

# SECURITIES & EXCHANGE COMMISSION EDGAR FILING

## Simulations Plus Inc.

**Form: 10-K**

**Date Filed: 2013-11-18**

Corporate Issuer CIK: 1023459

Symbol: SLP

SIC Code: 7373

Fiscal Year End: 08/31

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 10-K

T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended August 31, 2013

or

£ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-32046

**Simulations Plus, Inc.**

(Exact name of registrant as specified in its charter)

**California**

(State or other jurisdiction of incorporation or organization)

**95-4595609**

(I.R.S. Employer Identification No.)

**42505 Tenth Street West**

**Lancaster, CA 93534-7059**

(Address of principal executive offices including zip code)

**(661) 723-7723**

(Registrant's telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

**Title of Each Class**

Common Stock, par value \$0.001 per share

**Name of Each Exchange on Which Registered**

NASDAQ Stock Market LLC

SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes  No

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  No

The aggregate market value of the registrant's common stock held by non-affiliates of the registrant as of February 28, 2013, based upon the closing price of the common stock as reported by The Nasdaq Stock Market on such date, was approximately \$39,168,468.

This calculation does not reflect a determination that persons are affiliates for any other purposes.

As of November 15, 2013, 16,041,894 shares of the registrant's common stock, par value \$0.001 per share were outstanding, and no shares of preferred stock were outstanding.

#### **DOCUMENTS INCORPORATED BY REFERENCE**

Certain portions of the definitive Proxy Statement to be delivered to shareholders in connection with the 2014 Annual Meeting of Shareholders are incorporated by reference into Part III of this Form 10-K to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this annual report.

The Exhibit Index (Item 15) lists several documents incorporated by reference.

---

---

**Simulations Plus, Inc.**  
**FORM 10-K**  
**For the Fiscal Year Ended August 31, 2013**

Table of Contents

	<u>Page</u>
<b>PART I</b>	<b>3</b>
ITEM 1 – BUSINESS	3
ITEM 1A – RISK FACTORS	9
ITEM 1B – UNRESOLVED STAFF COMMENTS	9
ITEM 2 – PROPERTIES	9
ITEM 3 – LEGAL PROCEEDINGS	10
ITEM 4 – MINE SAFETY DISCLOSURES.	10
<b>PART II</b>	<b>10</b>
ITEM 5 – MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	10
ITEM 6 – SELECTED FINANCIAL DATA	10
ITEM 7 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	10
ITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	17
ITEM 8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	17
ITEM 9 – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	18
ITEM 9A – CONTROLS AND PROCEDURES	18
ITEM 9B – OTHER INFORMATION	18
<b>PART III</b>	<b>19</b>
ITEM 10 – DIRECTORS, AND EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE	19
ITEM 11 – EXECUTIVE COMPENSATION	19
ITEM 12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	19
ITEM 13 – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	19
ITEM 14 – PRINCIPAL ACCOUNTING FEES AND SERVICES	19
<b>PART IV</b>	<b>19</b>
ITEM 15 – EXHIBITS, FINANCIAL STATEMENT SCHEDULES	19
<b>SIGNATURES</b>	<b>21</b>

## Forward-Looking Statements

This document and the documents incorporated in this document by reference contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact contained in this document and the materials accompanying this document are forward-looking statements.

The forward-looking statements are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Frequently, but not always, forward-looking statements are identified by the use of the future tense and by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “could,” “would,” “projects,” “continues,” “estimates” or similar expressions. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those indicated by the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements.

The forward-looking statements contained or incorporated by reference in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements include declarations regarding our plans, intentions, beliefs or current expectations.

Among the important factors that could cause actual results to differ materially from those indicated by forward-looking statements are the risks and uncertainties described under “Risk Factors” in our other filings with the Securities and Exchange Commission (“SEC”).

Forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and we do not undertake any obligation to update forward-looking statements to reflect new information, subsequent events or otherwise.

## **PART I**

### **ITEM 1 – BUSINESS**

#### **OVERVIEW**

Simulations Plus, Inc. (“Simulations Plus” or the “Company,” “us,” “we,” or “our”), which was incorporated in 1996, develops and produces software for use in pharmaceutical research and for education, as well as provides consulting and contract research services to the pharmaceutical industry. Words+, founded in 1981, produced computer software and specialized hardware for use by persons with disabilities. The Words+ subsidiary was sold effective November 30, 2011, and is treated as “discontinued operations” in the financial statements. This discussion will therefore focus on the ongoing operations for pharmaceutical software and services.

#### **PRODUCTS**

We currently offer five software products for pharmaceutical research: ADMET Predictor™, MedChem Designer™, MedChem Studio™, DDDPlus™, and GastroPlus™. A sixth product, MembranePlus™, is well along in development with testing and validation studies under way. We plan to release MembranePlus™ by March 2014.

#### **ADMET Predictor™**

ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour on a fast laptop computer. This capability allows chemists to get estimates for a large number of important properties without the need to synthesize and test the molecules. ADMET Predictor has been consistently top-ranked in peer-reviewed, independent comparison studies for predictive accuracy, while generating its results at a very high throughput rate. The current state-of-the-art of this type of software does not enable finding the best molecule in a series, but it does allow identifying molecules that are highly likely to fail as potential drug candidates (the worst molecules, which is often the majority of a chemical library) before synthesizing and testing them. Thus, millions of “virtual” compounds can be created and screened in a day, compared to potentially months of work to actually synthesize and test a much smaller number of actual compounds.

The ADMET Modeler™ subprogram that is integrated into ADMET Predictor enables scientists to use their own experimental data to quickly create high-quality, proprietary predictive models using the same powerful modeling methods we use to build our top-ranked class property predictions. Pharmaceutical companies expend substantial time and money conducting a wide variety of experiments on new molecules each year, resulting in large databases of experimental data. Using this proprietary data to build predictive models can provide a second return on their investment; however, model building has traditionally been a difficult and tedious activity performed by specialists.

We released Version 6.5 of ADMET Predictor during this reporting period. This version extends our metabolism predictions by training on a much larger experimental data set, and for the first time, provides specific metabolism rates for individual atoms within a molecule, rather than only for the molecule as a whole. These improvements are also available via MedChem Designer and MedChem Studio for customers who license ADMET Predictor. We are now working on version 7.0, which we expect to release before the end of calendar 2013. This new version will incorporate a new model for predicting ionization constants (pKa's) developed in a collaboration with Bayer AG that enabled us to approximately double the size of our data set from about 16,000 pKa values to more than 30,000 and to expand the chemical space it covers to include more molecules representative of those of interest to the pharmaceutical industry today. We believe the resulting improvement in pKa prediction puts our already best-in-class model well in front of any competitor. Predicting ionization is critical to predicting most other properties, so all of our models (approximately 140) are being retrained based on this new capability for version 7.0.

Version 6.5 also adds confidence levels to most of our toxicity models so that users have an idea of the reliability of each individual prediction.

#### MedChem Designer™

MedChem Designer was launched in 2011. It was initially a molecule drawing program, or “sketcher”, but now has capabilities exceeding those of other molecule drawing programs because of its integration with both MedChem Studio and ADMET Predictor. We provide MedChem Designer for free because we believe that in the long run it will help to increase demand for ADMET Predictor and MedChem Studio, and because most other existing molecule drawing programs are also free. Our free version includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures and then see a few key properties very quickly. The chemist also sees that with a paid ADMET Predictor license, a total of over 140 predictions would be available.

When coupled with a license for ADMET Predictor, MedChem Designer becomes a de novo design tool for medicinal chemists. With it, they can draw one or more molecular structures, then click on the ADMET Predictor icon and have over 140 properties for each structure calculated in seconds, including our proprietary ADMET Risk™ index. They can also click on an icon to generate likely metabolites and predict their properties and ADMET Risks as well. ADMET Risk provides a single number that tells the chemist how many default threshold values for 24 predicted properties were crossed (or violated) by each structure. The rules can be modified and new rules added by the user to include any desired rule set based on any combination of calculated descriptors, predicted properties, and user inputs. Thus, in a single number, the chemist can instantly compare the effects of different structural changes in many dimensions. As chemists attempt to modify structures to improve one property, they often cause others to become unacceptable. Without ADMET Risk, the chemist would have to separately examine many key properties for each new molecule to check whether any became unacceptable as a result of changing the structure.

We released MedChem Designer 2.5 during this reporting period. This new version now shows the chemist the specific predicted atom locations for metabolism by each of the enzymes predicted to act upon a molecule.

#### MedChem Studio™

Over the past several years, MedChem Studio updates have resulted in a very powerful tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. We released version 3.5 of MedChem Designer during this reporting period. The new features are too numerous to list, but include such important items as:

- A new licensing module from Flexera called FlexNet™
- Improvements to graphics in structure depictions and the Miner 3D module
- Faster performance on large data sets
- A 64-bit version is now available to deal with much larger data sets

MedChem Designer can be used to refine a small number of molecules: however, creating and screening a very large number of molecules down to a few promising lead candidates is the primary function of MedChem Studio (with ADMET Predictor). MedChem Studio has features that enable it to generate very large numbers of new molecular structures using a variety of de novo design methods. Coupled with ADMET Predictor and MedChem Designer, we believe the programs provide an unmatched capability for chemists to search through large libraries of compounds that have undergone high-throughput screening experiments to find the most promising classes (groups of molecules with a large part of their structures the same) and molecules that are active against a particular target. In addition, MedChem Studio with ADMET Predictor can take an interesting (but not acceptable) molecule and very quickly generate many thousands of high quality analogs (i.e., similar new molecules) using a variety of design algorithms to generate new molecules that are predicted (via ADMET Predictor) to be both active against the target as well as acceptable in a variety of ADMET properties.

MedChem Studio version 3.5 was released during the current reporting period, adding a number of new features, including:

- New molecular structure drawing algorithms for crisper structure depictions
- New licensing module from Flexera called FlexNet™
- Increased execution speed
- 64-bit version accesses much more memory for very large data sets
- Ability for user to define equations to calculate new attributes by combining others
- Enhanced Miner3D graphics with expanded assortment of chart types

#### NCE Project

Based on our strong belief in our ADMET Design Suite's (MedChem Studio/MedChem Designer/ADMET Predictor) exceptional capabilities, we initiated our own project to design new molecules (NCEs, or New Chemical Entities). After considering various targets, we selected the malaria parasite *Plasmodium falciparum*, both because there is an unmet need for a very low-cost cure, and because we believed that external funding opportunities might exist if we were successful in generating high-quality lead compounds using our software. Our goal was to demonstrate how well the ADMET Design Suite worked to generate new lead molecules in a fraction of the time and cost normally required in the pharmaceutical industry. We completed the design process in September 2012 and we announced that we had requested quotations from chemical synthesis companies for the cost and time to make a small set of molecules. Five molecules of our own design and two precursors (almost the final designed structures, but a step away in synthesis) were synthesized and tested for inhibition of the parasite at the University of California at Riverside. We were hoping that at least one would show inhibition of the growth cycle of the parasite.

We were excited to learn that every molecule showed activity against the parasite at less than micromolar concentrations, with two showing activity at less than 100 nanomolar concentration (high potency) against the drug-sensitive strain of the parasite. They were then tested against the drug-resistant strain of the malaria parasite, and again potency was observed, with two molecules showing nanomolar activity. We believe this exercise – a software company using its own products to design novel molecules and have them synthesized and tested – is unprecedented.

Several of these molecules were sent to another outside laboratory for additional experiments to measure a few key properties to compare the values versus our ADMET Predictor predictions. Our predictions for solubility, ionization constants (pKa), and lipophilicity were all well within accepted tolerances. Metabolism by human liver microsomes was much faster than predicted, probably due to metabolism by pathways our models did not yet predict. These molecules were only expected to be good lead molecules, not to be final drug molecules. Further structural changes to these lead compounds might meet all requirements for an approved drug.

At this time, we are not pursuing this project any further using internal funding, but would do so if external funding can be secured, because our goal for this project was not to develop a cure for malaria. Rather, we wanted to demonstrate that our software tools can enable scientists to quickly and efficiently analyze high-throughput data, to generate new molecular structures, and to assess their qualities via ADMET Predictor, resulting in high-quality lead candidates in a small fraction of the time and cost usually required. We accomplished that and we have been presenting our results in scientific meetings and in webinars to a worldwide audience. New software license sales resulting from these presentations have already more than recovered our investment.

During this reporting period, we announced that we had completed the design of a number of new molecules for a different target – the cyclo-oxygenase-2 (COX-2) enzyme that is the target for Celebrex®. Celebrex is the only COX-2 inhibitor remaining on the market, after the withdrawal of other approved drugs (such as Vioxx®) due to cardiac toxicity. Our chemical synthesis contractor has been working on developing the synthetic methods to make these new molecules for a number of weeks and progress is encouraging. We hope to have samples of several of our new molecules, if not all of them, in the next few months, at which time we will contract for testing them against both COX-2 and COX-1 enzymes (COX-1 is inhibited by aspirin and other drugs). The reason for also testing against the COX-1 enzyme is that it appears from the scientific research that was conducted after the withdrawal of other COX-2 inhibitors from the market that it is important to inhibit both COX-2 and COX-1 at a certain ratio in order to provide the benefits of COX-2 inhibition without the cardiotoxicity risk that has been associated with inhibiting COX-2 alone. We designed our new molecules based on activity models for both COX-2 and COX-1 built from public data, with the goal of providing an acceptable ratio of COX-2 to COX-1 inhibition.

#### DDDPlus

DDDPlus simulates in vitro laboratory experiments used to measure the rate of dissolution of the drug and, if desired, the additives (excipients) contained in tablets and capsules under a variety of experimental conditions. This software program is used by formulation scientists in industry and the U.S. Food and Drug Administration (FDA) to (1) understand the physical mechanisms affecting the dissolution rate for various formulations, (2) reduce the number of cut-and-try attempts to design new drug formulations, and (3) to design in vitro dissolution experiments to better mimic in vivo conditions.

#### GastroPlus

Our flagship product and largest source of revenues is GastroPlus. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs administered to humans and animals, and is currently in widespread use at pharmaceutical companies, the FDA, the U.S. National Institutes of Health (NIH), and other government agencies in the U.S. and other countries. Because of GastroPlus, we were the only non-European company invited to join the European Innovative Medicines Initiative (IMI) program for Oral Bioavailability Tools (“OrBiTo”). OrBiTo is a collaboration among 27 industry, academic, and government organizations working in the area of oral absorption of pharmaceutical products. Because we are outside of Europe, our participation in this project is at our own expense, while other members are compensated for their work; however, we are a full member with access to all of the data and discussions of all other members. We believe participation in this initiative enables us to benefit from and to contribute to advancing the prediction of human oral absorption from preclinical data, and ensures that we are in front of the audience of member pharmaceutical companies and regulatory agencies.

Version 8.5 of GastroPlus was released during the current reporting period, adding a number of important new capabilities requested by customers as well as improvements we have identified in-house, including:

- A new model for precipitation based on classical nucleation theory
- Infant physiologies, including for babies born as much as 16 weeks premature
- A unique method for using transporter data from preclinical experiments to predict transporter effects in human and other animals
- A number of additional expression levels of enzymes and transporters in human and animal physiologies

#### MembranePlus™

MembranePlus is a new product that has been under development for a number of years, but was put on hold for several years due to other priorities. It was revived in the past year and is now nearing commercial release. Like DDDPlus, MembranePlus simulates laboratory experiments, but in this case, the experiments are for measuring permeability of drug-like molecules through various membranes, including several different cell cultures (Caco-2, MDCK) as well as artificially formulated membranes (PAMPA). The value of such a simulation is that when the same molecules are measured in different laboratories, results are often strikingly different. The differences are caused by a complex interplay of factors in how the experiment was set up. The ability to simulate these experiments with their specific setups in detail is provided by MembranePlus, and this enables the scientist to better interpret how results from various experiments can be used to predict permeability in human and animals, which is the ultimate goal. MembranePlus is unique and our customers have expressed significant interest in the new capability.

We plan to release version 1.0 of MembranePlus by March 2014.



## Contract Research and Consulting Services

Our expertise in oral absorption and pharmacokinetics is evidenced by the fact that our staff members have been speakers or presenters at over 80 scientific meetings worldwide in the past four years. We frequently conduct contracted studies for large customers (including the largest five pharmaceutical companies) who have particularly difficult problems and who recognize our expertise in solving them, as well as for smaller customers who prefer to have studies run by our scientists rather than to license our software and train someone to use it. The demand for our consulting services has been steadily increasing. Long-term collaborations and shorter-term consulting contracts serve both to showcase our technologies and to build and strengthen customer relationships.

During the fourth quarter of fiscal year 2013 we continued to work on our 5-year collaboration agreement with the Center for Food Safety and Applied Nutrition (CFSAN) of the FDA. FDA scientists and our scientists are using ADMET Predictor/Modeler to build predictive models for likely toxicities of food additives and contaminants. During the first year of this collaboration, we analyzed FDA databases and worked with FDA scientists to ensure that the FDA data to be used for building new predictive models is as accurate as we can reasonably make it. Both FDA scientists and our scientists are building a series of models to classify new compounds as toxic or nontoxic from FDA datasets. Included in this effort was a special modification to ADMET Predictor to allow the user to set a minimum value for specificity or sensitivity when building a model. Sensitivity refers to how well a model identifies toxic (or any other property) compounds. A model that determined all compounds are toxic would have 100% sensitivity, because all toxic compounds would be labeled as such; however, all nontoxic compounds would also be labeled toxic. Specificity refers to how well a model distinguishes between toxic and nontoxic compounds. Increasing one usually results in decreasing the other. Depending on the purpose of the model, some scientists will prefer to train models that emphasize one statistic over the other.

## **PRODUCT DEVELOPMENT**

Development of our software is focused on expanding product lines, designing enhancements to our core technology and integrating existing and new products into our principal software architecture and platform technology. We intend to offer regular updates to our products and to continue to look for opportunities to expand our existing product suite.

We develop all of our products internally. We have also licensed products or have otherwise acquired products, or portions of our products, from other organizations. These arrangements sometimes require the payment of royalties by us. We intend to continue to license or otherwise acquire technology or products from third parties. We currently have two royalty agreements, one with TSRL, Inc. ("TSRL") and another with Symyx Technologies ("Symyx"). In July 1997, we entered into a royalty agreement with TSRL pursuant to which royalties were paid to TSRL from revenues on each license for GastroPlus basic software. In March 2010, we entered into a royalty agreement with Symyx, which was merged with Accelrys, Inc., pursuant to which royalties were paid to Symyx from revenues on each license for Metabolite module. After we entered into a buyout agreement with Enslein Research, we combined Metabolism module and Metabolite module, and currently we pay royalties to Symyx from the sale of a new Metabolism module. These license agreements have no expiration date.

## **MARKETING AND DISTRIBUTION**

We market our pharmaceutical software and consulting services through attendance and presentations at scientific meetings, exhibits at trade shows, seminars at pharmaceutical companies and government agencies, through our web pages on the Internet, and using various communication media to our compiled database of prospects and customer names. At various scientific meetings around the world each year there are numerous presentations and posters presented in which the research that was reported on was performed using our software. Many of these presentations were from industry and FDA scientists; some were from our staff.

We have one independent distributor in Japan and two independent representatives in China; however, our scientific team is also the majority of our sales and marketing team, assisting our Vice President of Marketing and Sales and his staff with trade shows, seminars, and customer training both via the Internet and on-site. We believe that this is more effective than a completely separate sales team for several reasons: (1) customers appreciate talking directly with developers who can answer a wide range of technical questions about methods and features in depth; (2) our scientists benefit from direct customer contact by gaining an appreciation for the environment and problems of the customer; and (3) the relationships we build through scientist-to-scientist contact are stronger than through salesperson-to-scientist contacts.

We provide support to the GastroPlus User Group in Japan, which was organized by Japanese researchers several years ago. As of early 2013, a group of scientists in Europe and North America have organized another group following the example set in Japan. The number of members who have joined this group is more than 330. We support this group as well through coordination of online meetings each month and managing the web site for exchange of information among members.

We use the Internet to provide product information and software updates, and as a forum for user feedback and information exchange. We have cultivated market share in North America, South America, Europe, Japan, Australia, New Zealand, Singapore, and the People's Republic of China. Internet and e-mail technologies have had a positive influence on our ability to communicate with existing and potential customers worldwide.



## **PRODUCTION**

Our pharmaceutical software products are designed and developed entirely by our development team in California, with locations in Lancaster, Petaluma, San Jose, and San Diego. The principal materials and components used in the manufacture of simulation software products include CD-ROMs and instruction manuals, which are also produced in-house and through outside contractors. In-house graphic art and engineering talent enables us to accomplish this production in a cost-efficient manner.

## **COMPETITION**

In our pharmaceutical software and services business, we compete against a number of established companies that provide screening, testing and research services, and products that are not based on simulation software. There are also software companies whose products do not compete directly with, but are sometimes closely related to, ours. Our competitors in this field include some companies with financial, personnel, research and marketing resources that are larger than ours. Our management believes there is currently no significant competitive threat to GastroPlus or DDDPlus, however, one could be developed over time. MedChem Studio, MedChem Designer, and ADMET Predictor/ADMET Modeler operate in a more competitive environment. Several other companies presently offer simulation or modeling software, or simulation-software-based services, to the pharmaceutical industry.

Major pharmaceutical companies conduct drug discovery and development efforts through their internal development staffs and through outsourcing some of this work. Smaller companies generally need to outsource a greater percentage of this research. Thus, we compete not only with other software suppliers, but also with the in-house development teams at some of the larger pharmaceutical companies.

Although competitive products exist, both new licenses and license renewals for GastroPlus have continued to grow in spite of this competition. We believe that we enjoy a dominant market share in this segment. We believe that the success of our recent NCE project in which we designed, had synthesized, and tested a number of new molecules to treat malaria has cultivated strong interest in our ADMET Design Suite™ (ADMET Predictor/MedChem Studio/MedChem Designer). Presentations in the U.S., Japan, and Europe since the results were released have been well received and new licenses for our cheminformatics software have already more than recouped our investment. Our new COX-2/COX-1 NCE project is intended to further promote the abilities of our ADMET Design Suite for rapid and cost-effective design of lead compounds.

We believe the key factors in competing in this field are our ability to develop industry-leading simulation and modeling software and related products and services to effectively predict activities and ADMET-related behaviors of new drug-like compounds, to design new molecules with acceptable activity and ADMET properties, to develop and maintain a proprietary database of results of physical experiments that will serve as a basis for simulated studies and empirical models, to attract and retain a highly skilled scientific and engineering team, and to develop and maintain relationships with research and development departments of pharmaceutical companies, universities and government agencies.

We are actively seeking acquisitions to expand the pharmaceutical software and services business. Earlier attempts to acquire other companies have not been successful either in arriving at mutually agreeable terms and conditions, or because of adverse conditions discovered during our due diligence process.

## **TRAINING AND TECHNICAL SUPPORT**

Customer training and technical support are important factors in customer satisfaction for our pharmaceutical products, and we believe we are an industry leader in providing customer training and technical support in our business areas. We provide in-house seminars at customers', and potential customers', sites. These seminars often serve as initial training in the event the potential customer decides to license or evaluate our software. Technical support is provided after the sale of any software in the form of on-site training (at the customer's expense), web meetings, telephone, fax, and e-mail assistance to the customer's users during the customer's license period. We have used Internet meetings extensively to provide demonstrations and customer assistance, resulting in rapid response to requests worldwide and reducing our travel time and expenses.

Technical support for pharmaceutical software is provided by our life sciences team and our inside sales and support staff based at our headquarters facilities in Lancaster, California. We provide free telephone support offering toll-free numbers in the U.S. and Canada, and e-mail and web-based support for all of our pharmaceutical software products worldwide. Technical support for pharmaceutical software products is minimal, averaging a few person-hours per month.

## **RESEARCH AND DEVELOPMENT**

We believe that our ability to grow and remain competitive in our markets is strongly dependent on investment into research and development (“R&D”). R&D activities include both enhancement of existing products and development of new products. Development of new products and adding functionality to existing products are capitalized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 985-20, “Costs of Software to Be Sold Leased, or Marketed”. R&D expenditures, which primarily relate to both capitalized and expensed salaries, R&D supplies, laboratory testing, and R&D consulting, were approximately \$1,931,000 during fiscal year 2013, of which \$1,129,000 was capitalized. R&D expenditures during fiscal year 2012 were approximately \$1,907,000, of which \$959,000 was capitalized.

Our pharmaceutical business R&D activities during fiscal year 2013 were focused on improving our ADMET Predictor/ADMET Modeler, MedChem Studio, MedChem Designer and GastroPlus products, as well as the development of our new MembranePlus software product described above.

## **EMPLOYEES**

As of August 31, 2013, we employed 27 full-time employees and no part-time employees, including 19 in research and development, 4 in marketing and sales, 4 in administration and accounting. Currently 15 employees hold Ph.D.s and 1 is a Ph.D. candidate in their respective science or engineering disciplines. Additionally, 4 employees hold one or more Master’s degrees. Most of the senior management team and the members of our Board of Directors hold graduate degrees. We believe that our future success will depend, in part, on our ability to continue to attract, hire and retain qualified personnel. We continue to seek additions to our life sciences team although the competition for such personnel in the pharmaceutical industry is intense. None of our employees is represented by a labor union, and we have never experienced a work stoppage. We believe that our relations with our employees are good.

## **INTELLECTUAL PROPERTY AND OTHER PROPRIETARY RIGHTS**

We own two patents that were acquired as part of our acquisition of certain assets of Bioreason, Inc. We primarily protect our intellectual property through copyrights and trade secrecy. Our intellectual property consists primarily of source code for computer programs and data files for various applications of those programs in the pharmaceutical software businesses. The expertise of our staff is a considerable asset closely related to intellectual property, and attracting and retaining highly qualified scientists and engineers is essential to our business.

## **EFFECT OF GOVERNMENT REGULATIONS**

Our pharmaceutical software products are tools used in research and development and are neither approved nor approvable by the FDA or other government agencies.

## **ITEM 1A – RISK FACTORS**

Not applicable because we are a smaller reporting company.

## **ITEM 1B – UNRESOLVED STAFF COMMENTS**

Not applicable.

## **ITEM 2 – PROPERTIES**

We lease approximately 13,500 square feet of space in Lancaster, California. The original agreement had a five-year term with two (2), three (3)-year options to extend. Since the original five-year term expired in February 2011, we have exercised the first of the two (2), three (3)-year options which will end on February 2, 2014. We made an amendment to our current lease with a single remaining extension of three (3) years at an annual increase of 4% per year. The amended lease extends to February 2, 2017 with an annual increase of 3% per year and has an option of two (2) two-year extensions. The current base rent amount of \$24,272.42 per month remains the same; however, we had 3 months’ free base rent during the months of June, July and August of 2013. We record these three (3) months as a discount divided equally through the first term of this amended lease from June 2013 through January 2017. The amended lease is filed with the SEC as an exhibit to our Form 10-Q filed on July 10, 2013.

After the sale of Words+ to Prentke Romich Company (PRC), we entered into a sublease agreement under which Words+ paid 20% of the monthly rent we pay to our landlord, plus 20% of facility-related operating expenses. The term of this month to month sublease commenced on January 1, 2012 and ended on February 28, 2013.



### ITEM 3 – LEGAL PROCEEDINGS

We are not a party to any legal proceedings and are not aware of any pending legal proceedings of any kind.

### ITEM 4 – MINE SAFETY DISCLOSURES.

Not applicable.

## PART II

### ITEM 5 – MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

There is currently no share repurchase program pending, and the Company made no repurchases of its securities within the fourth quarter of the fiscal year 2013.

The following table shows low and high sales price for the Company's common stock for the last eight fiscal quarters.

	<u>Low Sales Price</u>	<u>High Sales Price</u>
FY13:		
Quarter ended August 31, 2013	4.01	4.83
Quarter ended May 31, 2013	3.92	4.39
Quarter ended February 29, 2013	4.01	4.59
Quarter ended November 30, 2012	4.38	4.80
FY12:		
Quarter ended August 31, 2012	3.76	4.46
Quarter ended May 31, 2012	3.66	4.61
Quarter ended February 29, 2012	2.91	4.25
Quarter ended November 30, 2011	2.97	3.24

### ITEM 6 – SELECTED FINANCIAL DATA

Not applicable because we are a smaller reporting company.

### ITEM 7 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*The following discussion and analysis should be read in conjunction with the Financial Statements and related notes included in this Annual Report on Form 10-K.*

#### **Management Overview**

#### **Fiscal year 2013 highlights:**

- *We released updated versions of all major software products.*
- *We advanced the development of our new MembranePlus™ software program for simulation of in vitro permeability experiment, which is now nearing completion.*
- *We completed two funded collaboration agreements with top-5 pharmaceutical companies to extend the capabilities of our flagship GastroPlus software with an enhanced oral cavity absorption model and the ability to simulate dosing through the skin.*
- *We successfully completed the second year of our five-year renewable collaboration with the Center for Food Safety and Nutrition of the FDA to develop predictive toxicity models for food additives and contaminants.*

- *We initiated a new drug design project targeting COX-2 and COX-1 enzymes and sent out requests for quotations for synthesis of these new molecules. After this reporting period we selected a contractor and development of the synthetic methods is now under way.*
- *We expanded our technical staff, adding 2 new Ph.D. scientists to the Life Sciences department and two additional engineers to form a new Computational Technologies (CT) team.*
- *Hosted 4 multi-day workshops in the United States and Europe to educate users on the various features & applications of our software*
- *Redesigned website with modern look and new interactive features*
- *Attended 55 scientific conferences, presenting 36 posters and oral podium lectures*
- *Achieved 94% renewal rate for software licenses over last 3 fiscal quarters*
- *Signed 60 new clients (includes new organizations and departments at existing clients)*
- *Finalized new orders for software licenses at several major regulatory agencies (including the U.S. FDA, U.S. EPA, and China SFDA)*
- *Achieved 27% increase in license revenue from Asian territories (Japan, China, Korea, Singapore, and Thailand).*
- *Assisted with the formation of the GastroPlus User Group, an interactive network of North American and European industry users that has created a forum for sharing best practices, addressing unmet needs, and promoting the adoption of modeling & simulation.*
- *In December 2012 during our first fiscal quarter of FY2013, the Board of Directors decided to pay an accelerated cash dividend consisting of all of the \$0.05 per share dividend planned for February 2013, plus \$0.03 of the planned dividends for May, August, and December 2013. This was done to provide shareholders with the benefit of the lower income tax rates in 2012 compared to the increased rates for 2013.*
- *Our Board of Directors declared increased (from \$0.02) quarterly cash dividends of \$0.03 per share in May and August. Recently, our Board of Directors declared a \$0.04/share dividend for November 15, 2013 distribution, which is in fiscal year 2014.*
- *Our cash position remained strong, with cash at the end of the fiscal year of \$10.2 million, and we have no debt.*

**Fiscal year 2013 Financial Summary:**

- *Gross revenues increased 6.6% to \$10,071,000 from \$9,449,000 in fiscal year 2012*
- *Selling, General and Administrative expenses increased 5.0% to \$3,550,000 from \$3,379,000 in fiscal year 2012*
- *Research and Development expenditures increased 1.3% to \$1,931,000 from \$1,907,000 in fiscal year 2012. In fiscal year 2012, approximately \$140,000 was spent for outside services to synthesize and test the new molecules we designed to inhibit the growth of the malaria parasite. In fiscal year 2013, we did not have such an expense, resulting appearance of small increase in research and development expenditure*
- *Income from continuing operations increased 11.7% to \$3,141,000 from \$2,812,000 in fiscal year 2012*

### **Strategy Going Forward:**

- *Continue to advance our software offerings through both our in-house developments and our funded and unfunded collaborations with our industry and government customers*
- *Continue to seek acquisition and partnership possibilities to broaden our offerings of products and services*
- *Continue our marketing and sales campaign including attending and exhibiting at numerous scientific conferences and meetings, expanded use of social media, and expanded advertising*
- *Increase our marketing and sales efforts with respect to our consulting services in both pharmacokinetics and in small molecule design*
- *Seek partners for our malaria new chemical initiative to take it further into development*
- *Select a new target and repeat our drug design, synthesis, and test activities as we did for malaria to further demonstrate the capabilities of our ADMET Design Suite to generate high-quality lead compounds in a fraction of the time and cost normally required*

Fiscal year 2013 was another record year. We believe the continued growth of our pharmaceutical software and services business segment is the result of steadily increasing adoption of simulation and modeling software tools across the pharmaceutical industry, as well as the expertise we offer as consultants to assist companies involved in the research and development of new medicines. We have received a continuing series of study contracts with pharmaceutical companies ranging from several of the largest in the world to a number of medium-sized and smaller companies in the U.S. and Europe.

Our financial performance enabled us to maintain significant cash deposits, remain debt-free, and continue to invest in our marketing and sales activities we began in early 2009 in order to reach a wider customer base, as well as to distribute significant cash dividends to our shareholders.

We have not been successful in identifying and completing any acquisitions during this reporting period in spite of ongoing investigations. It is our intent to continue to search for acquisition opportunities that would be compatible with our current businesses and that would be immediately accretive, i.e., adding to both revenues and earnings.

In the past, we have used some of our cash to repurchase shares of our common stock because we believe that reducing the number of fully diluted shares provides greater value to our shareholders than receiving a low interest rate on our cash deposits, and because we believe that our cash deposits after such repurchases remain sufficient to accomplish any reasonable potential acquisitions as well as to maintain sufficient cash reserves to ensure meeting operational needs for the foreseeable future. Although there are no stock repurchase programs pending, our Board of Directors may consider additional repurchases at any time at prices and under conditions set by our Board of Directors.

### **Results of Operations**

The following sets forth selected items from our statements of operations (in thousands) and the percentages that such items bear to net sales for the fiscal years ended August 31, 2013 ("FY13") and August 31, 2012 ("FY12").

	Fiscal years ended			
	08/31/13		08/31/12	
Net sales	\$ 10,071	100%	\$ 9,449	100%
Cost of sales	1,647	16.4	1,510	16.0
Gross profit	8,424	83.6	7,939	84.0
Selling, general and administrative	3,550	35.2	3,379	35.8
Research and development	802	8.0	948	10.0
Total operating expenses	4,352	43.2	4,327	45.8
Income from operations	4,072	40.4	3,612	38.2
Other income	184	1.8	343	3.6
Net income before taxes	4,256	42.3	3,955	41.9
(Provision) for income taxes	(1,370)	(13.6)	(1,143)	(12.1)
Income from continuing operations	2,886	28.7%	2,812	29.8%
Results of discontinued operations, net of tax	—	—	216	2.3
Net income	\$ 2,886	28.7%	\$ 3,028	32.1%





## **FY13 COMPARED WITH FY12**

### **Net Sales**

Net sales increased \$622,000, or 6.6%, to \$10,071,000 in FY13 from \$9,449,000 in FY12. We attribute the increase in pharmaceutical software sales to increases in the number of licenses with new and existing customers, as well as licensing of new modules to existing customers, especially for our GastroPlus line of products because it has more modules than other products we offer. The revenue from sales of software increased approximately \$254,000, or 3%. In FY13, the revenue from two funded collaborations which will expand the capabilities of our GastroPlus software and analytical studies also increased approximately \$368,000, or 101%.

### **Cost of Sales**

Cost of sales increased \$137,000, or 9.0%, to \$1,647,000 in FY13 from \$1,510,000 in FY12. As a percentage of net sales, cost of sales increased by 0.3%.

A significant portion of cost of sales is the systematic amortization of capitalized software development costs, which is an independent fixed cost rather than a variable cost related to sales. This amortization cost increased approximately \$49,000, or 7%, in FY13 compared with FY12.

Royalty expense, a variable cost related to sales of our GastroPlus core program as well as royalties from the agreement with Accelrys, Inc. (the original agreement was with Symyx Technologies which merged with Accelrys, Inc.) Metabolite/Metabolism, increased approximately \$46,000, or 8%, in FY13 compared with FY12.

Service cost, such as labor costs for trainings/workshops, analytical studies, and technical support, increased approximately \$42,000, or 71%, in FY13 compared with FY12 due to more number of person-hours allocated to those services during FY13 compared with FY12.

### **Gross Profit**

Gross profit increased \$485,000, or 6.1%, to \$8,424,000 in FY13 from \$7,939,000 in FY12. We attribute this increase to the increased sales of pharmaceutical software which outweighed an increase in the cost of goods sold.

### **Selling, General and Administrative Expenses**

Selling, general and administrative ("SG&A") expenses increased \$171,000, or 5.0% to \$3,550,000 in FY13, compared to \$3,379,000 in FY12; however, as a percentage of sales, SG&A decreased to approximately 35.2% in FY13 from approximately 35.8% in FY12. The major increases in SG&A expense were:

- Mergers and acquisitions consultant fees incurred in FY12 were converted to selling expense as part of the commission for the sale of our former Words+ subsidiary after the close of that sale. This conversion of consulting fees to selling expense (commission) gives the appearance of a \$105,000 increase in consulting fees in FY13 compared with FY12.
- Commission expense increased by \$50,000, or 22%, to \$275,000 in FY13 from \$225,000 in FY12. We incurred higher commissions to our dealers in Japan and China as they increased their sales.
- Insurance expense increased by \$45,000, or 24%, to \$236,000 in FY13 from \$191,000 in FY12 both from an increase in the number of employees, as well as an overall increase in insurance premiums with the largest increases in health insurance.

The major decreases in SG&A expense were:

- Advertising expense decreased by \$41,000, or 53%, to \$38,000 in FY13 from \$79,000 in FY12 due to ads placed for NCE (new chemical entity) malaria project in FY12 while no such ads were placed in FY13.
- Marketing, labor and travel costs decreased by \$83,000, or 56%, to \$66,000 in FY13 from \$149,000 in FY12. In FY12, we made significant efforts to expand our market share in China by sending life science personnel to China several times to demonstrate our products.

Professional fees paid to outside consultants decreased by \$77,000, or 34%, to \$150,000 in FY13 from \$227,000 in FY12. In FY12, we incurred extra tax consulting fees relating to the sale of Words+, valuation services, and legal services related to our attempt to acquire certain assets of Entelos in bankruptcy court, while such fees were not incurred in FY13.

Thus, increases in SG&A expenses outweighed decreases.

### Research and Development

We incurred approximately \$1,931,000 of research and development costs during FY13. Of this amount, \$1,129,000 was capitalized and \$802,000 was expensed. In FY12, we incurred \$1,900,000 of research and development costs, of which \$952,000 was capitalized and \$948,000 was expensed. The increase of \$24,000, or 1.3%, in total research and development expenditures from FY12 to FY13 was due to staff increases and salary increases for existing staff, which outweighed the reduction in NCE (new chemical entity) malaria project costs.

### Income from operations

During FY13, we generated income from operations of \$4,072,000, as compared to \$3,612,000 for FY12, an increase of 12.7%. We attribute this increase to increases in gross profit and decreases in research and development expense, which outweighed the increase in SG&A expense.

### Other Income and (Expense)

Net other income (expense) decreased by \$159,000, or 46.2%, to \$184,000 in FY13 from \$343,000 in FY12. This is due to the lower interest income and lower currency exchange gain in FY13 compared with FY12, and a decrease in sublease income from Words+ as they closed their operations in March 2013.

### Provision for Income Taxes

Provision for income taxes for FY13 increased by \$227,000, or 19.9%, to \$1,370,000, compared to \$1,143,000 for FY12 due to higher taxable income.

### Income from Continuing Operations

Net income from continuing operations for FY13 increased by \$74,000, or 2.7%, to \$2,886,000, compared to \$2,812,000 for FY12. We attribute this increase in net income to increased gross profit and decrease in research and development expense, and decrease in tax expense, which outweighed the increase in SG&A expense, the decrease in other income, and increase in tax expense.

## **SEASONALITY**

Sales in our business segment exhibits some seasonal fluctuations, with the fourth fiscal quarter (June-August) generally having the lowest sales over the past three fiscal years because of summer vacations and reduced activities at our customers' sites. This unaudited quarterly sales information has been prepared on the same basis as the annual information presented elsewhere in this Annual Report on Form 10-K and, in the opinion of management, reflects all adjustments (consisting of normal recurring entries) necessary for a fair presentation of the information presented. Net sales for any quarter are not necessarily indicative of sales for any future period; however, because our pharmaceutical software is licensed on an annual basis, renewals are usually within the same quarter year after year.

### **Net Sales (in thousands)**

<b>FY</b>	<b>First Quarter</b>	<b>Second Quarter</b>	<b>Third Quarter</b>	<b>Fourth Quarter</b>	<b>Total</b>
2013	2,290	3,118	3,095	1,568	10,071
2012	2,248	2,789	2,772	1,640	9,449
2011	2,050	2,622	2,640	1,427	8,739
2010	1,735	2,227	2,325	1,334	7,621
2009	1,430	1,779	1,985	1,107	6,301
2008	1,438	1,550	1,975	1,092	6,055
2007	824	1,808	1,659	1,465	5,756
2006	199	884	1,096	1,007	3,186
2005	524	410	662	473	2,069
2004	642	742	603	869	2,856
2003	507	582	614	1,403	3,106

## **LIQUIDITY AND CAPITAL RESOURCES**

Our principal source of capital has been cash flow from our operations. We have achieved continuous positive operating cash flow over the last nine fiscal years. We believe that our existing capital and anticipated funds from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the foreseeable future. Thereafter, if cash generated from operations is insufficient to satisfy our capital requirements, we may open a revolving line of credit with a bank, or we may have to sell additional equity or debt securities or obtain expanded credit facilities. In the event such financing is needed in the future, there can be no assurance that such financing will be available to us, or, if available, that it will be in amounts and on terms acceptable to us.



We are not aware of any trends or demands, commitments, events or uncertainties that are reasonably likely to result in a decrease in liquidity of our assets. The trend over the last ten years has been increasing cash deposits from our operating cash flows, and we expect that trend to continue for the foreseeable future. We have no material commitments for capital expenditures as of the end of the latest fiscal period.

We continue to seek opportunities for strategic acquisitions. If one or more such acquisitions is identified, a substantial portion of our cash reserves may be required to complete it; however, we intend to maintain sufficient cash reserves after any acquisition to provide reasonable assurance that outside financing will not be necessary to continue operations. If we identify an attractive acquisition that would require more cash to complete than we are willing or able to use from our cash reserves, we will consider financing options to complete the acquisition, including obtaining loans and issuing additional securities.

Because we have not been able to find suitable acquisitions for several years, the board of directors decided to distribute a portion of our cash reserves to our shareholders, declaring an ongoing \$0.05 per share per quarter cash dividend beginning with the second quarter of FY12. Quarterly dividend payments made in FY12 and FY13 are listed in the following table.

Record Date	Distribution Date	Number of Shares Outstanding on Record Date	Dividend per Share	Total Amount
2/21/2012	3/1/2012	15,813,844	\$ 0.05	\$ 790,692
4/27/2012	5/8/2012	15,923,019	\$ 0.05	\$ 796,151
8/7/2012	8/10/2012	15,923,019	\$ 0.05	\$ 796,151
11/8/2012	11/13/2012	15,927,806	\$ 0.05	\$ 796,390
12/24/2012	12/28/2012	16,021,309	\$ 0.14*	\$ 2,242,983
5/7/2013	5/10/2013	16,030,433	\$ 0.03**	\$ 480,913
8/12/2013	8/15/2013	16,030,894	\$ 0.03**	\$ 480,926

\* As a tax benefit to our shareholders considering the increase in federal income tax for capital gains in 2013, the Board of Directors declared an accelerated cash dividend, \$0.14 per share, on December 14, 2012, consisting of all of the planned February 2013 distribution of \$0.05 per share, plus \$0.03 per share of the planned \$0.05 per quarter per share for the remaining three fiscal quarters ending in calendar year 2013.

\*\* The Board of Directors decided to increase the May and August dividend distributions by 50% from the planned \$0.02/share to \$0.03/share.

There can be no assurances that our Board of Directors will continue the dividend distributions for any specified number of quarters; however, there is no current plan to discontinue the quarterly dividend distributions. After the end of this reporting period, our Board of Directors declared a dividend distribution of \$0.04 per share for November 2013, an increase of 100% over the planned \$0.02 per share that remained after the accelerated distribution in December 2012.

### **UNUSUAL OR INFREQUENT EVENTS**

On November 30, 2011, we sold our entire interest in our former wholly-owned subsidiary, Words+, an augmentative and alternative communication device manufacturer, for aggregate gross proceeds of \$1.97 million. We recognized a gain of approximately \$465,820, net of tax, from the sale of Words+, which is included in discontinued operations in our statement of operations for the fiscal year ended August 31, 2012. The difference between the sales price and the net gain is a result of adjustments to net working capital from August 31, 2011, until the closing on November 30, 2011, legal fees, auditing fees, tax specialist's fees, and severance compensation for terminated employees.

### **KNOWN TRENDS OR UNCERTAINTIES**

Although we have not seen any significant reduction in revenues to date, we have seen consolidation in the pharmaceutical industry during the current economic downturn. This trend has not had a negative effect on our total sales to that industry; however, these consolidations and downsizing in the industry could have an impact on our revenues and earnings going forward.

We believe that the need for improved productivity in the research and development activities directed toward developing new medicines will continue to result in increasing adoption of simulation and modeling tools such as those we produce. New product developments in the pharmaceutical business segments could result in increased revenues and earnings if they are accepted by our markets; however, there can be no assurances that new products will result in significant improvements to revenues or earnings. For competitive reasons, we do not disclose all of our new product development activities.

Our continued quest for acquisitions in the pharmaceutical business segment could result in a significant change to revenues and earnings if one or more such acquisitions are completed.



## **INFLATION**

We have not been affected materially by inflation during the periods presented, and no material effect is expected in the near future.

## **OFF-BALANCE SHEET ARRANGEMENTS**

As of August 31, 2013, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

We do not have relationships or transactions with persons or entities that derive benefits from their non-independent relationship with us or our related parties.

## **RECENTLY ISSUED OR NEWLY ADOPTED ACCOUNTING STANDARDS**

In July 2012, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update 2012-02, *Testing Indefinite-Lived Intangible Assets for Impairment* ("ASU 2012-02"), which amended the guidance in Accounting Standards Update 2011-08 Testing Goodwill for Impairment to simplify the testing of indefinite-lived intangible assets other than goodwill for impairment. ASU 2012-02 becomes effective for annual and interim impairment tests performed for fiscal years beginning on or after September 15, 2012 and earlier adoption is permitted. We adopted this standard in the first quarter of fiscal year 2013. We believe adoption did not have a material effect on our financial statements.

## **SIGNIFICANT ACCOUNTING POLICIES**

### Estimates

Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. Actual results could differ from those estimates. Significant accounting policies for us include revenue recognition, accounting for capitalized software development costs, and accounting for income taxes.

### Revenue Recognition

We recognize revenues related to software licenses and software maintenance in accordance with the FASB Accounting Standards Codification ("ASC") 985-605, "Software – Revenue Recognition". Software products revenue is recorded when the following conditions are met: 1) evidence of arrangement exists; 2) delivery has been made; 3) the amount is fixed; and 4) collectability is probable. Post-contract customer support ("PCS") obligations are insignificant; therefore, revenue for PCS is recognized at the same time as the licensing fee, and the costs of providing such support services are accrued and amortized over the obligation period.

As a byproduct of ongoing improvements and upgrades for the new programs and new modules of software, some modifications are provided to our customers who have already purchased software at no additional charge. Other software modifications result in new, additional cost modules that expand the functionality of the software. These are licensed separately. We consider the modifications that are provided without charge to be minimal, as they do not significantly change the basic functionality or utility of the software, but rather add convenience, such as being able to plot some additional variable on a graph in addition to the numerous variables that had been available before, or adding some additional calculations to supplement the information provided from running the software. Such software modifications for any single product have typically occurred once or twice per year, sometimes more, sometimes less. Thus, they are infrequent. The Company provides, for a fee, additional training and service calls to its customers and recognizes revenue at the time the training or service call is provided.

Generally, we enter into one-year license agreements with customers for the use of our pharmaceutical software products. We recognize revenue on these contracts when all the criteria are met.

Most license agreements have a term of one year; however, from time to time, we enter into multi-year license agreements. We generally unlock and invoice software one year at a time for multi-year licenses. Therefore, revenue is recognized one year at a time.

We recognize the revenue from collaboration research and the revenue from grants equally over their terms. However, we recognize the contract study revenue using the percentage of completion method, depending upon how the contract studies are engaged, in accordance with FASB ASC 605-35, "Revenue Recognition – Construction-Type and Production-Type Contracts". To recognize revenue using the percentage of completion method, we must determine whether we meet the following criteria: 1) there is a long-term, legally enforceable contract and 2) it is possible to reasonably estimate the total project costs, and 3) it is possible to reasonably



estimate the extent of progress toward completion.

### Capitalized Computer Software Development Costs

Software development costs are capitalized in accordance with FASB ASC 985-20, "Costs of Software to Be Sold, Leased, or Marketed". Capitalization of software development costs begins upon the establishment of technological feasibility and is discontinued when the product is available for sale.

The establishment of technological feasibility and the ongoing assessment for recoverability of capitalized software development costs require considerable judgment by management with respect to certain external factors including, but not limited to, technological feasibility, anticipated future gross revenues, estimated economic life, and changes in software and hardware technologies. Capitalized computer software development costs are comprised primarily of salaries and direct payroll-related costs and the purchase of existing software to be used in the Company's software products.

Amortization of capitalized computer software development costs is provided on a product-by-product basis on the straight-line method over the estimated economic life of the products (not to exceed five years). Amortization of software development costs amounted to \$716,888 and \$668,021 for the years ended August 31, 2013 and 2012, respectively. We expect future amortization expense to vary due to increases in capitalized computer software development costs.

We test capitalized computer software development costs for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

### Income Taxes

We utilize FASB ASC 740-10, "Income Taxes", which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

The California Franchise Tax Board ("FTB") audited us for the fiscal years ended ("FYE") August 31, 2007 and 2008. We received refunds as we claimed; however they continued their audit to include fiscal years 2009 and 2010, and were reviewing 2007 and 2008 R&D credits, since those credits were carried forward to FYE 2009 and 2010. In May 2013, we received a letter from the FTB stating that an audit will not be conducted for those years at this time; however it may be subject to future audit if they receive new information.

In March 2012, we also received a notice from the Internal Revenue Service (IRS) that our fiscal year ended August 31, 2008 was subject to their examination. In October 2012, the IRS completed their examination of our 2007 tax filing. The outcome of this examination was a decrease of \$36,868 in the amount refundable. We received a refund of \$151,246 in December 2012.

### Stock-Based Compensation

We account for stock options using the modified prospective method in accordance with FASB ASC 718-10, *Compensation-Stock Compensation* ("FASB 718-10"). Under this method, compensation costs include: (1) compensation cost for all share-based payments granted prior to, but not yet vested as of September 1, 2006, based on the grant-date fair value estimated in accordance with the original provisions of Statement of Financial Accounting Standards No. 123 amortized over the options' vesting period, and (2) compensation cost for all share-based payments granted subsequent to September 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of FASB ASC 718-10, amortized on a straight-line basis over the options' vesting period. Stock-based compensation was \$115,740 and \$181,521 for the fiscal years ended August 31, 2013 and 2012, respectively, and is included in the consolidated statements of operations as Consulting, Salaries, and Research and Development expense.

## **ITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable because we are a smaller reporting company.

## **ITEM 8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

The responses to this item are included elsewhere in this Form 10-K (see pages F1 – F23) and incorporated herein by reference.

## **ITEM 9 – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE**

There have been no changes to our public accountants during the past two years.

## **ITEM 9A – CONTROLS AND PROCEDURES**

We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to provide reasonable assurance that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on our management's evaluation (with the participation of our principal executive officer and principal financial officer) of our disclosure controls and procedures as required by Rule 13a-15(b) and 15d-15(b) under the Exchange Act, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of August 31, 2013, the end of the fiscal year covered by this report.

### Management's Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal controls over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal controls over financial reporting are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal controls over financial reporting based on the framework established by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under such framework, including the completion and review of internal review assessment forms and the completion and review of financial reporting information systems and controls checklists in the framework, our management concluded that our internal control over financial reporting was effective as of August 31, 2013.

No changes were made in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended August 31, 2013, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or internal controls over financial reporting will prevent all errors or all instances of fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitation of a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## **ITEM 9B – OTHER INFORMATION**

Not applicable.

## **PART III**

### **ITEM 10 – DIRECTORS, AND EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE**

#### Code of Ethics

Our code of ethics is posted on our website: [www.simulations-plus.com](http://www.simulations-plus.com).

#### Changes to Procedures for Recommending Nominees to the Board of Directors

There have been no material changes to the procedures by which security holders may recommend nominees to our board of directors since we last described such procedures.

The remaining information required by Item 10 is incorporated by reference from the sections entitled “Board Matters and Corporate Governance,” “Election of Directors,” “Executive Compensation and Other Information,” and “Security Ownership of Certain Beneficial Owners and Management” in our definitive proxy statement on Schedule 14A (the “Proxy Statement”) to be distributed in connection with our 2014 Annual Shareholders’ Meeting.

### **ITEM 11 – EXECUTIVE COMPENSATION**

The information required by Item 11 is incorporated by reference from the sections entitled “Executive Compensation and Other Information” and “Board Matters and Corporate Governance” in our Proxy Statement to be distributed in connection with our 2014 Annual Shareholders’ Meeting.

### **ITEM 12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

The information required by Item 12 is incorporated by reference from the sections entitled “Security Ownership of Certain Beneficial Owners and Management” and “Executive Compensation and Other Information” in our Proxy Statement to be distributed in connection with our 2014 Annual Shareholders’ Meeting.

### **ITEM 13 – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

The information required by Item 13 is incorporated by reference from the subsection entitled “Certain Relationships and Related Transactions; Transactions with Related Persons” and the section entitled “Board Matters and Corporate Governance” in our Proxy Statement to be distributed in connection with our 2014 Annual Shareholders’ Meeting.

### **ITEM 14 – PRINCIPAL ACCOUNTING FEES AND SERVICES**

The information required by Item 14 is incorporated by reference from the section of the proposal entitled “Ratification of Selection of Independent Registered Public Accounting Firm” in our Proxy Statement to be distributed in connection with our 2014 Annual Shareholders’ Meeting.

## **PART IV**

### **ITEM 15 – EXHIBITS, FINANCIAL STATEMENT SCHEDULES**

(a) (1) Financial Statements. The consolidated financial statements are included in this Annual Report.

(2) Financial Statement Schedules. All financial statement schedules have been omitted since the information is either not applicable or required or was included in the financial statements or notes included in this Annual Report on Form 10-K

(3) List of Exhibits required by Item 601 of Regulation S-K. See part (b) below.

(b) Exhibits. The following exhibits are filed as part of this report. Those exhibits marked with a (†) refer to management contracts or compensatory plans or arrangements.

<u>EXHIBIT NUMBER</u>	<u>DESCRIPTION</u>
3.1	Articles of Incorporation of the Company. (5)
3.2	Amended and Restated Bylaws of the Company. (5)
4.1	Articles of Incorporation of the Company. (incorporated by reference to Exhibit 3.1 hereof)
4.2	Bylaws of the Company. (incorporated by reference to Exhibit 3.2 hereof)
4.3	Form of Common Stock Certificate (1)
4.4	Share Exchange Agreement (1)
10.1	The Company's 1996 Stock Option Plan (the "Option Plan") and forms of agreements relating thereto (1)
10.2	Exclusive License Software Agreement by and between the Company and Therapeutic Systems Research Laboratories dated June 30, 1997. (2)
10.3	The Company's 2007 Stock Option Plan. (3)
10.4	Notice of Election to Extend Term of Lease by and between the Company and Crest Development LLC formerly Freeway Ventures LLC, dated July 29, 2010.(4)
10.5	Employment Agreement by and between the Company and Walter S. Woltosz, dated as of July 22, 2011. (5) (†)
10.6	Bill of Sale by and between the Company and Entelos, Inc. dated September 19, 2011. (6)
10.7	Stock Purchase Agreement by and among the Company, Words+, Inc., and Prentke Romich Company dated November 15, 2011. (7)
10.8	Amended lease agreement by and between the Company and Crest Development LLC, dated May 23, 2013. (8)
10.9	Employment Agreement by and between the Company and Walter S. Woltosz, dated as of August 22, 2013. (9) (†)
23.1	Consent of Independent Registered Public Accounting Firm (9)
31.1	Section 302 – Certification of the Principal Executive Officer. (9)
31.2	Section 302 – Certification of the Principal Financial Officer. (9)
32.1	Section 906 – Certification of the Chief Executive Office and Chief Financial Officer. (9)
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

- (1) Incorporated by reference to the Company's Registration Statement on Form SB-2 (Registration No. 333-6680) filed on March 25, 1997.
- (2) Incorporated by reference to the Company's Form 10-KSB for the fiscal year ended August 31, 1997.
- (3) Incorporated by reference to the Company's Form 10-K for the fiscal year ended August 31, 2009.
- (4) Incorporated by reference to the Company's Form 10-K for the fiscal year ended August 31, 2010.
- (5) Incorporated by reference to the Company's Form 10-K for the fiscal year ended August 31, 2011.
- (6) Incorporated by reference to the Company's Form 8-K filed September 22, 2011.
- (7) Incorporated by reference to the Company's Form 8-K filed November 16, 2011.
- (8) Incorporated by reference to the Company's Form 10-Q filed July 10, 2013.
- (9) Filed herewith

(c) Financial Statement Schedule.

See Item 15(a)(2) above.

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lancaster, State of California, on November 15, 2013.

SIMULATIONS PLUS, INC.

By: /s/ Momoko A. Beran

Momoko A. Beran  
Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title
<u>/s/ Walter S. Woltosz</u> Walter S. Woltosz November 15, 2013	Chairman of the Board of Directors and Chief Executive Officer (Principal executive officer)
<u>/s/ Virginia E. Woltosz</u> Virginia E. Woltosz November 15, 2013	Secretary and Director of the Company
<u>/s/ Dr. David Z. D'Argenio</u> Dr. David Z. D'Argenio November 15, 2013	Director
<u>/s/ Dr. David L. Ralph</u> Dr. David L. Ralph November 15, 2013	Director
<u>/s/ Harold W. Rosenberger</u> Harold W. Rosenberger November 15, 2013	Director
<u>/s/ Momoko A. Beran</u> Momoko A. Beran November 15, 2013	Chief Financial Officer of the Company (Principal financial officer and principal accounting officer)

	<u>Page</u>
<b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b>	F-2
<b>FINANCIAL STATEMENTS</b>	
Balance Sheets	F-3
Statements of Operations	F-4
Statements of Shareholders' Equity	F-5
Statements of Cash Flows	F-6
Notes to Financial Statements	F-7 – F23

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of  
Simulations Plus, Inc.  
Lancaster, California

We have audited the accompanying balance sheets of Simulations Plus, Inc. (a California corporation) as of August 31, 2013 and 2012 and the related statements of operations, shareholders' equity and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards established by the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Simulations Plus, Inc. as of August 31, 2013 and 2012, and the results of its operations and cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Rose, Snyder & Jacobs LLP

Encino, California

November 15, 2013



**SIMULATIONS PLUS, INC.**  
**BALANCE SHEETS**  
As of

<b>ASSETS</b>	<b>August 31,</b>	
	<b>2013</b>	<b>2012</b>
<b>Current assets</b>		
Cash and cash equivalents	\$ 10,179,298	\$ 12,701,075
Prepaid income taxes	301,573	153,896
Accounts receivable, net of allowance for doubtful accounts of \$0	1,910,615	1,451,864
Contracts receivable	203,913	18,893
Prepaid expenses and other current assets	192,173	150,856
Deferred income taxes	184,258	193,712
Total current assets	12,971,830	14,670,296
<b>Long-term assets</b>		
Capitalized computer software development costs, net of accumulated amortization of \$5,801,578 and \$5,084,690	2,891,169	2,479,468
Property and equipment, net (note 3)	117,987	107,410
Intellectual property, net of accumulated amortization of \$11,250 and \$3,750	63,750	71,250
Other assets	18,445	18,445
<b>Total assets</b>	<b>\$ 16,063,181</b>	<b>\$ 17,346,869</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 146,011	\$ 177,509
Accrued payroll and other expenses	311,209	312,912
Accrued bonuses to officer	60,000	60,000
Accrued income taxes	-	733,233
Other current liabilities	19,859	-
Deferred revenue	89,227	131,782
Total current liabilities	626,306	1,415,436
<b>Long-term liabilities</b>		
Deferred income taxes	1,146,389	788,857
Other long-term liabilities	47,993	-
Total liabilities	1,820,688	2,204,293
<b>Commitments and contingencies (note 4)</b>		
<b>Shareholders' equity (note 5)</b>		
Preferred stock, \$0.001 par value 10,000,000 shares authorized no shares issued and outstanding	-	-
Common stock, \$0.001 par value 50,000,000 shares authorized 16,030,894 and 15,927,806 shares issued and outstanding	4,502	4,399
Additional paid-in capital	4,842,794	4,628,366
Retained earnings	9,395,197	10,509,811
Total shareholders' equity	14,242,493	15,142,576
<b>Total liabilities and shareholders' equity</b>	<b>\$ 16,063,181</b>	<b>\$ 17,346,869</b>

The accompanying notes are an integral part of these financial statements.

**SIMULATIONS PLUS, INC.**  
**STATEMENTS OF OPERATIONS**  
For the years ended

	August 31,	
	2013	2012
<b>Net sales</b>	\$ 10,070,770	\$ 9,448,608
<b>Cost of sales</b>	1,646,530	1,510,148
<b>Gross profit</b>	8,424,240	7,938,460
<b>Operating expenses</b>		
Selling, general, and administrative	3,549,495	3,379,017
Research and development	802,374	947,556
Total operating expenses	4,351,869	4,326,573
<b>Income from operations</b>	4,072,371	3,611,887
<b>Other income (expense)</b>		
Interest income	49,492	89,265
Miscellaneous income	35,488	76,149
Gain on currency exchange	99,429	177,790
Gain on sale of assets	–	(433)
Interest expense	–	(3)
Total other income (expense)	184,409	342,768
<b>Income from continuing operations before provision for income taxes</b>	4,256,780	3,954,655
<b>Provision for income taxes (note 6)</b>	(1,370,182)	(1,142,693)
<b>Income from continuing operations</b>	\$ 2,886,598	\$ 2,811,962
<b>Discontinued operations:</b>		
Gain (loss) from discontinued operations, net of tax	–	(249,898)
Gain on sale of Words+, net of tax	–	465,820
Results of discontinued operations	–	215,922
<b>Net Income</b>	\$ 2,886,598	\$ 3,027,884
<b>Basic earnings per share:</b>		
Continuing operations	\$ 0.18	\$ 0.18
Discontinued operations	–	0.01
Net basic earnings per share	\$ 0.18	\$ 0.19
<b>Diluted earnings per share</b>		
Continuing operations	\$ 0.18	\$ 0.18
Discontinued operations	–	0.01
Net diluted earnings per share	\$ 0.18	\$ 0.19
<b>Weighted-average common shares outstanding</b>		
Basic	15,996,432	15,763,674
Diluted	16,319,983	16,151,873

The accompanying notes are an integral part of these financial statements.

**SIMULATIONS PLUS, INC.**  
**STATEMENTS OF SHAREHOLDERS' EQUITY**  
For the years ended

	<u>Common Stock</u>		<u>Additional Paid-In Capital</u>	<u>Retained Earnings</u>	<u>Total</u>
	<u>Shares</u>	<u>Amount</u>			
<b>Balance, August 31, 2011</b>	15,572,943	\$ 4,044	\$ 4,167,650	\$ 9,864,921	\$ 14,036,615
<b>Exercise of stock options</b>	354,863	355	301,286		301,641
<b>Stock-based Compensation</b>			181,521		181,521
<b>Deferred tax adjustments</b>					
- Change in prior year tax refund			(36,868)		(36,868)
- Current deferred tax adjustments			14,777		14,777
<b>Declaration of Dividend</b>				(2,382,994)	(2,382,994)
<b>Net income</b>				3,027,884	3,027,884
<b>Balance, August 31, 2012</b>	<u>15,927,806</u>	<u>\$ 4,399</u>	<u>\$ 4,628,366</u>	<u>\$ 10,509,811</u>	<u>\$ 15,142,576</u>
<b>Exercise of stock options</b>	103,088	103	27,882		27,985
<b>Stock-based Compensation</b>			115,740		115,740
<b>Excess tax benefits from share-based arrangement</b>	70,806		70,806		
<b>Declaration of Dividend</b>				(4,001,212)	(4,001,212)
<b>Net income</b>				2,886,598	2,886,598
<b>Balance, August 31, 2013</b>	<u>16,030,894</u>	<u>\$ 4,502</u>	<u>\$ 4,842,794</u>	<u>\$ 9,395,197</u>	<u>\$ 14,242,493</u>

The accompanying notes are an integral part of these financial statements.

**SIMULATIONS PLUS, INC.**  
**STATEMENTS OF CASH FLOWS**  
For the years ended

	<u>2013</u>	<u>2012</u>
<b>Cash flows from operating activities</b>		
Net income	\$ 2,886,598	\$ 3,027,884
Adjustments to reconcile net income to net cash provided by operating activities		
(Income) from Discontinued Operations	–	(215,922)
Depreciation and amortization of property and equipment	42,573	41,802
Amortization of customer relationships	–	1,871
Amortization of capitalized computer software development costs	716,887	668,021
Amortization of Intellectual property	7,500	3,750
Excess tax benefits from share-based arrangement	(70,806)	22,091
Stock-based compensation	115,740	127,738
(Gain)/Loss from sale of assets	–	433
Deferred income taxes	366,986	207,617
(Increase) decrease in		
Accounts receivable and Contracts receivable	(643,771)	(114,080)
Prepaid income taxes	(147,677)	105,538
Prepaid expenses and other assets	(41,317)	(26,903)
Increase (decrease) in		
Accounts payable	(31,498)	1,372
Accrued payroll and other expenses	(1,703)	28,798
Accrued bonus	–	60,000
Accrued income taxes	(662,427)	542,245
Other liabilities	67,852	–
Deferred revenue	(42,555)	(9,409)
Net cash provided by operating activities of continuing operations	<u>2,562,382</u>	<u>4,472,846</u>
Net cash provided by (used in) operating activities of discontinued operations	–	(688,862)
Net cash provided by operating activities	<u>2,562,382</u>	<u>3,783,984</u>
<b>Cash flows from investing activities</b>		
Proceeds from sale of Words+, Inc.	–	1,973,096
Proceeds from sale of assets	–	200
Purchases of property and equipment	(53,150)	(106,835)
Purchase of royalty	–	(75,000)
Capitalized computer software development costs	(1,128,588)	(958,507)
Net cash provided by (used in) investing activities of continuing operations	<u>(1,181,738)</u>	<u>832,954</u>
Net cash provided by (used in) investing activities of discontinued operations	–	6,532
Net cash provided by (used in) investing activities	<u>(1,181,738)</u>	<u>839,486</u>
<b>Cash flows from financing activities</b>		
Excess tax benefits from share-based arrangement	70,806	(22,091)
Dividends	(4,001,212)	(2,382,994)
Proceeds from the exercise of stock options	27,985	301,641
Net cash (used in) financing activities of continuing operations	<u>(3,902,421)</u>	<u>(2,103,444)</u>
<b>Net increase (decrease) in cash and cash equivalents from continuing operations</b>	<u>(2,521,777)</u>	<u>3,202,356</u>
<b>Net (decrease) in cash and cash equivalents from discontinued operations</b>	<u>–</u>	<u>(682,330)</u>
<b>Net increase (decrease) in cash and cash equivalents</b>	<u>(2,521,777)</u>	<u>2,520,026</u>
<b>Cash and cash equivalents, beginning of year</b>	<u>12,701,075</u>	<u>10,181,049</u>
<b>Cash and cash equivalents, end of period</b>	<u>\$ 10,179,298</u>	<u>\$ 12,701,075</u>
<b>Supplemental disclosures of cash flow information</b>		
Interest paid	\$ –	\$ 3
Income taxes paid	<u>\$ 1,964,545</u>	<u>\$ 457,000</u>

The accompanying notes are an integral part of these financial statements.



**NOTE 1 - ORGANIZATION AND LINES OF BUSINESS**

Organization

Simulations Plus, Inc. (the "Company", "we", "us", "our") was incorporated on July 17, 1996. On August 29, 1996, the shareholders of Words+, Inc. ("Words+") exchanged their 2,000 shares of Words+, Inc. common stock for 2,200,000 (Pre-split) shares of Simulations Plus, Inc. common stock, and Words+ became a wholly-owned subsidiary of Simulations Plus, Inc. The Words+ subsidiary was sold effective November 30, 2011, and is treated as "discontinued operations" in the accompanying financial statements.

Lines of Business

The Company designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The Company also developed and sells a productivity software program called Abbreviate! that was moved from the Words+ subsidiary to Simulations Plus, Inc.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

Use of Estimates

Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. Actual results could differ from those estimates.

Principles of Consolidation

The financial statements of Simulations Plus, Inc. include the accounts of Words+ up to November 30, 2011 (FY12), the date of sale of the wholly-owned subsidiary. All significant intercompany accounts and transactions were eliminated in consolidation. The operations of Words+ are presented as "discontinued operations" in the financial statements.

Revenue Recognition

We recognize revenues related to software licenses and software maintenance in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 985-605, "*Software - Revenue Recognition*": Software products revenue is recorded when the following conditions are met: 1) evidence of arrangement exists, 2) delivery has been made, 3) the amount is fixed, and 4) collectability is probable. Post-contract customer support ("PCS") obligations are insignificant; therefore, revenue for PCS is recognized at the same time as the licensing fee, and the costs of providing such support services are accrued and amortized over the obligation period.

As a byproduct of ongoing improvements and upgrades for the new programs and new modules of software, some modifications are provided to customers who have already purchased software at no additional charge. Other software modifications result in new, additional cost modules that expand the functionality of the software. These are licensed separately. We consider the modifications that are provided without charge to be minimal, as they do not significantly change the basic functionality or utility of the software, but rather add convenience, such as being able to plot some additional variable on a graph in addition to the numerous variables that had been available before, or adding some additional calculations to supplement the information provided from running the software. Such software modifications for any single product have typically occurred once or twice per year, sometimes more, sometimes less. Thus, they are infrequent. The Company provides, for a fee, additional training and service calls to its customers and recognizes revenue at the time the training or service call is provided.

Generally, we enter into one-year license agreements with customers for the use of our pharmaceutical software products. We recognize revenue on these contracts when all the criteria are met.

Most license agreements have a term of one year; however, from time to time, we enter into multi-year license agreements. We generally unlock and invoice software one year at a time for multi-year licenses. Therefore, revenue is recognized one year at a time.

We recognize the revenue from collaboration research and the revenue from grants equally over their terms. However, we recognize the contract study revenue using the percentage of completion method, depending upon how the contract studies are engaged, in accordance with ASC 605-35, "*Revenue Recognition – Construction-Type and Production-Type Contracts*." To recognize revenue using the percentage of completion method, we must determine whether we meet the following criteria: 1) there is a long-term, legally enforceable contract, 2) it is possible to reasonably estimate the total project costs, and 3) it is possible to reasonably estimate the extent of progress toward completion.

#### Cash and Cash Equivalents

For purposes of the statements of cash flows, the Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

#### Accounts Receivable

We analyze the age of customer balances, historical bad debt experience, customer creditworthiness, and changes in customer payment terms when making estimates of the collectability of the Company's trade accounts receivable balances. If we determine that the financial conditions of any of our customers have deteriorated, whether due to customer-specific or general economic issues, an increase in the allowance may be made. Accounts receivable are written off when all collection attempts have failed. The Company also estimated the contractual discount obligation for third party funding such as Medicaid and private insurance companies. Those estimated discounts were reflected in the allowance for doubtful accounts and contractual discounts and included in discontinued operations. Although we experienced significant collection problems with our former Words+ subsidiary, we have not had customers fail to pay on the pharmaceutical software and services side of the business, which now represents our entire business after the sale of our former subsidiary on November 30, 2011.

Capitalized Computer Software Development Costs

Software development costs are capitalized in accordance with ASC 985-20, "Costs of Software to Be Sold, Leased, or Marketed". Capitalization of software development costs begins upon the establishment of technological feasibility and is discontinued when the product is available for sale.

The establishment of technological feasibility and the ongoing assessment for recoverability of capitalized software development costs require considerable judgment by management with respect to certain external factors including, but not limited to, technological feasibility, anticipated future gross revenues, estimated economic life, and changes in software and hardware technologies. Capitalized computer software development costs are comprised primarily of salaries and direct payroll-related costs and the purchase of existing software to be used in the Company's software products.

Amortization of capitalized computer software development costs is provided on a product-by-product basis on the straight-line method over the estimated economic life of the products (not to exceed five years). Amortization of software development costs amounted to \$716,888 and \$668,021 for the years ended August 31, 2013 and 2012, respectively. We expect future amortization expense to vary due to increases in capitalized computer software development costs.

We test capitalized computer software development costs for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over the estimated useful lives as follows:

Equipment	5 years
Computer equipment	3 to 7 years
Furniture and fixtures	5 to 7 years
Leasehold improvements	Shorter of life of asset or lease

Maintenance and minor replacements are charged to expense as incurred. Gains and losses on disposals are included in the results of operations.

Fair Value of Financial Instruments

Assets and liabilities recorded at fair value in the Company's Balance Sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories, as defined by the standard, are as follows:



<b>Level Input:</b>	<b>Input Definition:</b>
Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II	Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III	Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at August 31, 2013 for assets and liabilities measured at fair value on a recurring basis:

	<b>Level I</b>	<b>Level II</b>	<b>Level III</b>	<b>Total</b>
Cash and cash equivalents	\$ 10,179,298	\$ –	\$ –	\$ 10,179,298
<b>Total assets</b>	<b>\$ 10,179,298</b>	<b>\$ –</b>	<b>\$ –</b>	<b>\$ 10,179,298</b>

For certain of our financial instruments, including accounts receivable, accounts payable, accrued payroll and other expenses, accrued bonuses to officers, and accrued warranty and service costs, the carrying amounts are approximate fair value due to their short-term nature.

#### Advertising

The Company expenses advertising costs as incurred. Advertising costs for the years ended August 31, 2013 and 2012 were \$38,000 and \$79,000, respectively.

#### Research and Development Costs

Research and development costs are charged to expense as incurred until technological feasibility has been established. These costs include salaries, laboratory experiment, and purchased software which was developed by other companies and incorporated into, or used in the development of, our final products.

#### Income Taxes

The Company accounts for income taxes in accordance with ASC 740-10, "Income Taxes" which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

**SIMULATIONS PLUS, INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**August 31, 2013 and 2012**

The California Franchise Tax Board (“FTB”) audited us for the fiscal years ended (“FYE”) August 31, 2007 and 2008. We received refunds as we claimed; however they continued their audit to include FYE 2009 and 2010, and are reviewing 2007 and 2008 R&D credits since those credits were carried forward to FYE 2009 and 2010. In May 2013, we received a letter from FTB stating that an audit will not be conducted for those years at this time; however it may be subject to future audit if they receive new information.

In March 2012, we also received a notice from the Internal Revenue Service (“IRS”) that our FYE 2008 is subject to their examination. In October 2012, the IRS completed their examination of our 2007 tax filing. The outcome of this examination was a decrease of \$36,868 in the amount refundable. We received a refund of \$151,246 in December 2012.

Intellectual property

On February 28, 2012, we bought out the royalty agreement with Enslein Research of Rochester, New York. The cost of \$75,000 is being amortized over 10 years under the straight-line method. Amortization expense for the fiscal year ended August 31, 2013 and 2012 was \$7,500 and \$3,750, respectively. Accumulated amortization as of August 31, 2013 and 2012 was \$11,250 and \$3,750, respectively.

Earnings per Share

The Company reports earnings per share in accordance with FASB ACS 260-10. Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similarly to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The components of basic and diluted earnings per share for the years ended August 31, 2013 and 2012 were as follows:

	2013	2012
<b>Numerator</b>		
Net income attributable to common shareholders	<b>\$ 3,141,384</b>	<b>\$ 3,027,884</b>
<b>Denominator</b>		
Weighted-average number of common shares outstanding during the year	15,996,432	15,763,674
Dilutive effect of stock options	323,551	388,199
<b>Common stock and common stock equivalents used for diluted earnings per share</b>	<b>16,319,983</b>	<b>16,151,873</b>

Stock-Based Compensation

The Company accounts for stock options using the modified prospective method in accordance with FASB ASC 718-10, "Compensation-Stock Compensation". Under this method, compensation costs include: (1) compensation cost for all share-based payments granted prior to, but not yet vested as of September 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of Statement of Financial Accounting Standard ("SFAS") No. 123 amortized over the options' vesting period, and (2) compensation cost for all share-based payments granted subsequent to September 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS No. 123R, amortized on a straight-line basis over the options' vesting period. Stock-based compensation was \$115,740 and \$181,521 for the years ended August 31, 2013 and 2012, respectively, and is included in the statements of operations as Consulting, Salaries, and Research and Development expense.

Recently Issued Accounting Standards

In July 2012, the FASB issued Accounting Standards Update ("ASU") 2012-02, "Testing Indefinite-Lived Intangible Assets for Impairment" ("ASU 2012-02"), which amended the guidance in ASU 2011-08, "Intangibles-Goodwill and Other (Topic 350): Testing Goodwill for Impairment" to simplify the testing of indefinite-lived intangible assets other than goodwill for impairment. ASU 2012-02 becomes effective for annual and interim impairment tests performed for fiscal years beginning on or after September 15, 2012 and earlier adoption is permitted. We adopted this standard in the first quarter of FYE 2013. We believe adoption did not have a material effect on our financial statements.

**NOTE 3 – PROPERTY AND EQUIPMENT**

Property and equipment at August 31, 2013 and 2012 consisted of the following:

	2013	2012
Equipment	\$ 141,355	\$ 123,062
Computer equipment	295,174	272,562
Furniture and fixtures	53,096	48,813
Leasehold improvements	61,860	53,898
	<u>551,485</u>	<u>498,335</u>
Less accumulated depreciation and Amortization	433,498	390,925
<b>Total</b>	<b><u>\$ 117,987</u></b>	<b><u>\$ 107,410</u></b>

Depreciation expense was \$42,573 and \$41,802 for the years ended August 31, 2013 and 2012, respectively.

**NOTE 4 - COMMITMENTS AND CONTINGENCIES**

Leases

Our original lease for approximately 13,500 square feet of space was under a five-year term with two (2), three (3)-year options to extend the lease. The base rent was \$18,445 per month plus common area maintenance fees with annual 4% increase on the base rent. We made an amendment to our original lease which will end on February 2, 2014 with one remaining extension of three (3) years at an annual increase of 4% per year. The amended lease extends to February 2, 2017-, with an annual increase of 3% per year and has an option of two (2) two (2)-year extensions. The current base rent amount of \$24,272 per month remains the same; however, we have three (3) months' free base rent during the months of June, July and August of 2013. We will record these three (3) months as a discount divided equally through the first term of this amended lease from June 2013 through January 2017. The amended lease is filed with the Securities and Exchange Commission ("SEC") as an exhibit in our Quarterly Report on Form 10-Q for the fiscal quarter ended May 31, 2013 filed with the SEC on July 10, 2013.

Rent expense, including common area maintenance fees for the year ended August 31, 2013 and 2012 were \$305,636 and \$293,089, respectively.

After the sale of Words+, we entered into a month to month sublease agreement commencing January 1, 2012 under which Words+ pays 20% of the monthly rent we pay to our landlord, plus 20% of facility-related operating expenses. We report our gross lease expense under Selling, General and Administrative expense; however, the sublease payments received from Words+ are reported under Other Income. The sublease to Words+ ended at February 28, 2013, when it closed its business operation.

Future minimum lease payments under non-cancelable operating leases with remaining terms of one year or more at August 31, 2013 were as follows:

Years Ending August 31,	
2014	\$ 291,269
2015	297,094
2016	306,007
2017	129,526
	\$ 1,023,896

On October 30, 2006, the Company entered into an equipment lease agreement. In this agreement, the Company leased a Ricoh Copier/Printer for 36 months with the option of earlier termination with a 60-day written notice. On October 30, 2009, we renewed the same agreement for another 36 months with an increment of 1 cent per copy on color printing which reflects their material cost. On April 17, 2012, we entered into a new lease agreement with ARC, a successor of Ricoh, former leasing company, for 36 months under the same term as the existing agreement which we pay as we use.

Employment Agreement

On August 22, 2013, the Company entered into an employment agreement with its President/Chief Executive Officer that expires in August 2014. The employment agreement provides for an annual base salary of \$300,000 per year, and a performance bonus in an amount equal to 5% of the Company's net income before taxes of the previous fiscal year, not to exceed \$60,000. The agreement also provides Employee stock options, exercisable for five years, to purchase ten (10) shares of Common Stock for each one thousand dollars (\$1,000) of net income before taxes at the end of each fiscal year up to a maximum of 20,000 options over the term of the agreement. The Company may terminate the agreement upon 30 days written notice if termination is without cause. The Company's only obligation would be to pay its President the greater of a) 12 months salary or b) the remainder of the term of the employment agreement from the date of notice of termination.

For fiscal year 2013, the Compensation Committee awarded a \$30,000 performance bonus to Walter Woltosz, our President/Chief Executive Officer, which was paid in September 2013.

For fiscal year 2012, the Compensation Committee awarded a \$30,000 performance bonus to Walter Woltosz, our President/Chief Executive Officer, which was paid in September 2012.

License Agreement

In 1997, the Company entered into an agreement with Therapeutic Systems Research Laboratory ("TSRL") to develop a computer simulation software program of the absorption of drug compounds in the gastrointestinal tract. Upon execution of a definitive License Agreement on July 9, 1997, TSRL received an initial payment of \$75,000, and thereafter, the Company is obligated to pay a royalty of 20% of the net sales of the basic GastroPlus software without additional modules.

In September 2007, we entered into an agreement with Enslein Research, Inc. ("Enslein") to jointly create a new metabolism module as part of ADMET Predictor. The fee for the exclusive license to the Enslein Data, in the form of a royalty, is 50% of the gross sales revenues of the ADMET Predictor Enslein Metabolism Module, and a \$50,000 bonus at the time the cumulative revenue from ADMET Predictor Enslein Metabolism Module sales reaches \$250,000. On February 28, 2012, we signed a buyout agreement with Enslein for \$75,000, and are amortizing its cost over 10 years after this date.

We also have a royalty agreement with Accelrys, Inc. (the original agreement was entered into with Symyx Technologies in March 2010; Symyx Technologies later merged with Accelrys, Inc.) for Metabolite Database access for developing our Metabolite module which was renamed as Metabolism module when we released ADMET Predictor version 6 on April 19, 2012. Under this agreement, we pay 25% of revenue derived from the sale of Metabolism/Metabolite module.

For the years ended August 31, 2013 and 2012, we incurred total royalty expense of approximately \$646,000 and \$601,000, respectively.

Legal Matters

We are not a party to any litigation at this time and we are not aware of any pending litigation of any kind.

**NOTE 5 - SHAREHOLDERS' EQUITY**

Dividend

The Company's Board of Directors declared cash dividends during fiscal year 2013 and 2012. The details of dividend paid are in the following table:

Record Date	Distribution Date	FY2013		Total Amount
		Number of Shares Outstanding on Record Date	Dividend per Share	
11/08/2012	11/13/2012	15,927,806	\$ 0.05	\$ 796,390
12/24/2012	12/28/2012	16,021,309	\$ 0.14*	\$ 2,242,983
05/07/2013	05/10/2013	16,030,433	\$ 0.03**	\$ 480,913
08/12/2013	08/15/2013	16,030,894	\$ 0.03**	\$ 480,926
<b>Total</b>				<b>\$ 4,001,212</b>

\*As a tax benefit to our shareholders considering the increase in federal income tax for capital gains in 2013, the Company's Board of Directors declared an accelerated cash dividend, \$0.14 per share, on December 14, 2012, consisting of all of the planned February 2013 distribution of \$0.05 per share, plus \$0.03 per share of the planned \$0.05 per quarter per share for the remaining three fiscal quarters ending in calendar year 2013.

\*\* The Company's Board of Directors decided to increase the May and August dividend distribution by 50% from the planned \$0.02/share to \$0.03/share. Although dividend distributions are currently expected to continue on a quarterly basis, the Company's Board of Directors reserves the right to discontinue the dividend distribution any time to meet the cash priorities of the business.

Record Date	Distribution Date	FY2012		Total Amount
		Number of Shares Outstanding on Record Date	Dividend per Share	
02/21/2012	03/01/2012	15,813,844	\$ 0.05	\$ 790,692
04/27/2012	05/08/2012	15,923.019	\$ 0.05	\$ 796,151
08/07/2012	08/10/2012	15,923.019	\$ 0.05	\$ 796,151
<b>Total</b>				<b>\$ 2,382,994</b>

Stock Option Plan

In September 1996, the Company's Board of Directors adopted, and the Company's shareholders approved, the 1996 Stock Option Plan (the "Option Plan") under which a total of 1,000,000 shares of common stock had been reserved for issuance. In March 1999, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 2,000,000. In February 2000, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 4,000,000. In December 2000, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 5,000,000. Furthermore, in February 2005, the shareholders approved an additional 1,000,000 shares, resulting in the total number of shares that may be granted under the Option Plan of 6,000,000. The 1996 Stock Option Plan terminated in September 2006 by its term.

**SIMULATIONS PLUS, INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**August 31, 2013 and 2012**

On February 23, 2007, the Company's Board of Directors adopted and the Company's shareholders approved the 2007 Stock Option Plan under which a total of 1,000,000 shares of common stock had been reserved for issuance.

Qualified Incentive Stock Options ("Qualified ISO")

As of August 31, 2013, employees hold Qualified ISO to purchase 532,000 shares of the Company's common stock at exercise prices ranging from \$1.00 to \$5.06 which were granted prior to August 31, 2013.

Transactions in FY12 (Incentive Stock Option Plan)	Number of Options	Weighted-Average Exercise Price Per Share	Weighted- Average Remaining Contractual Life
Outstanding, August 31, 2011	957,636	\$ 1.40	5.220
Granted	100,000	\$ 3.25	
Exercised	(360,736)	\$ 1.22	
Expired	(7,100)	\$ 2.54	
Outstanding, August 31, 2012	689,800	\$ 1.74	4.523
Vested and Exercisable, August 31, 2012	467,100	\$ 1.42	4.071
Vested and Expected to Vest, August 31, 2012	666,789	\$ 1.71	4.451

Transactions in FY13 (Incentive Stock Option Plan)	Number of Options	Weighted-Average Exercise Price Per Share	Weighted- Average Remaining Contractual Life
Outstanding, August 31, 2012	689,800	\$ 1.74	4.523
Granted	20,000	\$ 5.06	
Exercised	(175,800)	\$ 1.90	
Canceled/Forfeited	(2,000)	\$ 1.00	
Outstanding, August 31, 2013	532,000	\$ 1.82	3.953
Vested and Exercisable, August 31, 2013	392,600	\$ 1.45	3.798
Vested and Expected to Vest, August 31, 2013	519,600	\$ 1.79	3.912

Non-Qualified Stock Options ("NQSO")

As of August 31, 2013, the outside members of the Company's Board of Directors hold options to purchase 48,600 shares of the Company's common stock at exercise prices ranging from \$1.67 to \$6.68, which were granted prior to August 31, 2013.

**SIMULATIONS PLUS, INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**August 31, 2013 and 2012**

Transactions in FY12	Number of Options	Weighted-Average Exercise Price Per Share	Weighted- Average Remaining Contractual Life
Outstanding, August 31, 2011	79,000	\$ 2.29	5.150
Granted	10,000	\$ 4.46	
Exercised	(40,800)	\$ 1.25	
Canceled/Forfeited	(11,600)	\$ 4.10	
Outstanding, August 31, 2012	36,600	\$ 3.47	8.139
Exercisable, August 31, 2012	17,000	\$ 3.35	6.975

Transactions in FY13	Number of Options	Weighted-Average Exercise Price Per Share	Weighted- Average Remaining Contractual Life
Outstanding, August 31, 2012	36,600	\$ 3.47	8.139
Granted	12,000	\$ 4.78	
Outstanding, August 31, 2013	48,600	\$ 3.79	7.845
Exercisable, August 31, 2013	28,200	\$ 3.28	6.671

The fair value of the options, including both ISO and NQSO options, granted during FYE 2013 is estimated at \$30,200. The fair value of these options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions for FYE 2013: dividend yield of 4.35%, pre-vest forfeiture rate of 6.13%, expected volatility of 57.65%, risk-free interest rate of 0.66%, and expected life of 5.0 years. The total fair value of non-vested stock options as of August 31, 2013 was \$194,956 and is amortizable over a weighted average period of 1.37 years.

During the previous fiscal year ended August 31, 2012, the fair value of the options, including both ISO and NQSO options, granted during FYE 2012 is estimated at \$167,124. The fair value of these options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions for FYE 2012: dividend yield of 0.41%, pre-vest forfeiture rate of 5.61% to 6.09%, expected volatility of 62.27% to 69.87%, risk-free interest rate of 0.82% to 1.01%, and expected life of 5.0 years to 7.0 years. The total fair value of non-vested stock options as of August 31, 2012 was \$292,426 and is amortizable over a weighted average period of 2.03 years.



The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

Intrinsic Value of options outstanding and options exercisable

	Intrinsic Value of Options Outstanding	Intrinsic Value of Options Exercisable	Intrinsic Value of Options Exercised
FY12	\$ 1,918,904	\$ 1,447,900	\$ 982,786
FY13	\$ 1,636,422	\$ 1,357,870	\$ 402,406

The weighted-average remaining contractual life of options outstanding issued under the Plan was 4.28 years at August 31, 2013. The exercise prices for the options outstanding at August 31, 2012 ranged from \$1.00 to \$6.68, and the information relating to these options is as follows:

Exercise Price		Awards Outstanding			Awards Exercisable		
Low	High	Quantity	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Quantity	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price
\$1.00	\$1.50	353,100	3.9 years	\$1.06	319,700	3.8 years	\$1.07
\$1.51	\$3.00	34,600	6.5 years	\$2.30	14,600	6.3 years	\$2.04
\$3.01	\$4.50	156,900	4.1 years	\$3.26	82,500	4.4 years	\$3.18
\$4.51	\$6.68	36,000	6.0 years	\$5.15	4,000	4.0 years	\$6.68
		<b>580,600</b>			<b>420,800</b>		

**NOTE 6 - INCOME TAXES**

We utilize FASB ASC 740-10, "Income Taxes" which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

**SIMULATIONS PLUS, INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**August 31, 2013 and 2012**

The components of the income tax provision for FYE 2013 and 2012 were as follows:

	<u>2013</u>	<u>2012</u>
Current		
Federal	\$ 891,153	\$ 872,907
State	112,042	177,975
	<u>1,003,195</u>	<u>1,050,882</u>
Deferred		
Federal	57,805	114,712
State	309,182	(22,901)
	<u>366,987</u>	<u>91,811</u>
<b>Total</b>	<b><u>\$ 1,370,182</u></b>	<b><u>\$ 1,142,693</u></b>

A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company's effective income tax rate is as follows for FYE 2013 and 2012:

	<u>2013</u>	<u>2012</u>
Income tax computed at federal statutory tax rate	34.0%	34.0%
State taxes, net of federal benefit	5.2	3.3
Meals & Entertainment	0.1	0.1
Other permanent differences	(0.5)	0.8
Research and development credit	(11.3)	(8.4)
Change in prior year estimated taxes	4.7	(0.9)
<b>Total</b>	<b><u>32.2%</u></b>	<b><u>28.9%</u></b>

Significant components of the Company's deferred tax assets and liabilities for income taxes for FYE 2013 and 2012 are as follows:

	<u>2013</u>	<u>2012</u>
Deferred tax assets		
Accrued payroll and other expenses	\$ 82,104	\$ 79,922
Deferred revenue	38,225	56,456
Deferred rent	29,068	-
Property and equipment	-	32,916
Intellectual property	30,326	-
Research and development credit	-	261,526
State taxes	45,343	66,902
State Tax Deferred	74,458	-
Total deferred tax assets	<u>299,524</u>	<u>497,722</u>
Less: Valuation allowance	-	-
	<u>299,524</u>	<u>497,722</u>
Deferred tax liabilities		
Property and equipment	(23,077)	-
State Tax Deferred	(30,663)	-
Capitalized computer software development costs	(1,238,578)	(1,062,204)
Total deferred tax liabilities	<u>(1,261,655)</u>	<u>(1,092,867)</u>
<b>Net deferred tax liabilities</b>	<b><u>\$ (962,131)</u></b>	<b><u>\$ (595,145)</u></b>

We follow guidance issued by the FASB with regard to its accounting for uncertainty in income taxes recognized in the financial statements. Such guidance prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled \$6,357 and \$1,300 for FYE 2013 and 2012, respectively. We file income tax returns with the IRS and the FTB. FTB audited us for FYE2007 and 2008. We received refunds as we claimed; however they continued their audit to include FYE 2009 and 2010, and were reviewing 2007 and 2008 research and development credits since those credits were carried forward to FYE 2009 and 2010. In May 2013, we received a letter from FTB stating that an audit will not be conducted for those years at this time; however it may be subject to future audit for the FYE 2007 through FYE 2010 if they receive new information.

In March 2012, we also received a notice from the IRS that our FYE 2008 is subject to their examination. In October 2012, the IRS completed their examination of our 2007 tax filing. The outcome of this examination was a decrease of \$36,868 in the amount refundable. We received a refund of \$151,246 in December 2012.

Our review of prior year tax positions using the criteria and provisions presented in guidance issued by FASB did not result in a material impact on the Company's financial position or results of operations.

**NOTE 7 – CONCENTRATIONS AND UNCERTAINTIES**

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and trade accounts receivable. The Company holds cash and cash equivalents at banks located in California, with balances that often exceed FDIC insured limits. Historically, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. However, considering the current banking environment, the Company is investigating alternative ways to minimize its exposure to such risks. While the Company may be exposed to credit losses due to the nonperformance of its counterparties, the Company does not expect the settlement of these transactions to have a material effect on its results of operations, cash flows or financial condition.

Revenue concentration shows that International sales accounted for 48% and 49% of net sales for FYE 2013 and 2012, respectively. Two customers (one is a dealer account representing various customers) accounted for 9% and 6% of net sales for FYE 2013. For FYE 2012, two customers accounted for 10% (one is a dealer account representing various customers) and 6% of net sales.

Accounts receivable concentration shows that two customers comprised 27% and 22% (a dealer account representing various customers) of accounts receivable at August 31, 2013, and two customers comprised 28% (a dealer account representing various customers) and 22% of accounts receivable at August 31, 2012.

We operate in the computer software industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.

The majority of our customers are in the pharmaceutical industry. During the current economy downturn, we have seen consolidation in the pharmaceutical industry. Although we have not seen any significant reduction in revenues to date, continued consolidation and downsizing in the pharmaceutical industry could have an impact on our revenues and earnings going forward.

**NOTE 8 - GEOGRAPHIC REPORTING**

The Company allocates revenues to geographic areas based on the locations of its customers. Geographical revenues were as follows for FYE 2013 and 2012:

(in '000)	North America	Europe	Asia	South America	Total
August 31, 2013	\$ 5,203	\$ 2,980	\$ 1,882	\$ 6	\$ 10,071
August 31, 2012	\$ 4,805	\$ 2,986	\$ 1,633	\$ 25	\$ 9,449

**NOTE 9 – RELATED PARTY TRANSACTIONS**

During FYE 2013, included in bonus expenses to officers was \$90,000, of which \$60,000 was accrued bonus representing 5% of the Company's FYE 2012 net income before bonuses and taxes, not exceeding \$60,000, paid to the Corporate Secretary, Virginia Woltosz, as an annual bonus as part of the terms of the sale of Words+ to Simulations Plus, Inc. in 1996. The other \$30,000, paid in September 2012, was FYE 2012 performance bonus to Walter Woltosz, our President/Chief Executive Officer. As of August 31, 2013, \$60,000 was accrued and unpaid.

During FYE 2012, included in bonus expenses to officers was \$87,500, of which \$60,000 was accrued bonus representing 5% of the Company's FYE 2012 net income before bonuses and taxes, not exceeding \$60,000, paid to the Corporate Secretary, Virginia Woltosz, as an annual bonus as part of the terms of the sale of Words+ to Simulations Plus in 1996. The other \$27,500, paid in December 2011, was FYE 2011 performance bonus to Walter Woltosz, our President/Chief Executive Officer.

**NOTE 10 – CUSTOMER RELATIONSHIPS**

The Company purchased customer relationships as a part of the acquisition of certain assets of Bioreason, Inc. in November 2005. Customer relationships was recorded at a cost of \$128,042 and is being amortized over 78 months under the sum-of-the-years'-digits method. Amortization expense for FYE 2013 and 2012 amounted to \$0 and \$1,870, respectively. Accumulated amortization was \$128,042 as of August 31, 2012 and the net book value of \$0 was removed from the company's accounts during FYE 2013.

**NOTE 11 - EMPLOYEE BENEFIT PLAN**

We maintain a 401(k) Plan for all eligible employees. We make matching contributions equal to 100% of the employee's elective deferral, not to exceed 4% of the total employee compensation. We can also elect to make a profit-sharing contribution. Contributions by the Company to this Plan amounted to \$104,162 and \$89,258 for FYE 2013 and 2012, respectively.

**NOTE 12 - DISCONTINUED OPERATIONS**

On November 30, 2011, we sold our interest in Words+ for \$1,973,096 in cash. Words+ operations are now presented as discontinued operations in accordance with accounting rules related to the disposal of long-lived assets.

**SIMULATIONS PLUS, INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**August 31, 2013 and 2012**

We recognized a gain of \$465,820, net of tax, from this sale, which is included in income from discontinued operations in our statement of operations for the fiscal quarter ended November 30, 2011. The revenue and expenses of discontinued operations for the first fiscal quarter of 2012 are as follows:

(in thousands)	Period from 09/01/11 to 11/30/11
Net sales	\$ 479
Cost of sales	265
Gross profit	<u>214</u>
Selling, general and administrative	563
Research and development	55
Total operating expenses	<u>618</u>
Income (Loss) from discontinued operations	<u>(404)</u>
Other income	-
Income (Loss) from discontinued operations before income taxes	<u>(404)</u>
(Provision for) income taxes	154
Results from discontinued operations, net of tax	<u><u>\$ (250)</u></u>

The carrying amount of the assets and liabilities of discontinued operations just prior to the date of the sale on November 30, 2011 were as follows:

(in thousands)	11/30/11
Cash and cash equivalents	\$ 6
Receivables, net	357
Inventory	392
Prepaid and other current assets	33
Capitalized software development costs, net	212
Property and equipment, net	91
<b>Total Assets</b>	<b><u>1,091</u></b>
Accounts payable	72
Accrued payroll and other expenses	109
Accrued warranty and service costs	37
<b>Total Liabilities</b>	<b><u>218</u></b>
<b>Net Assets of discontinued operations</b>	<b><u><u>\$ 873</u></u></b>

**NOTE 13 - SUBSEQUENT EVENTS**

On October 29, 2013, our Board of Directors declared the next quarterly cash dividend of \$0.04 per share to our shareholders. The dividend will be distributed on Friday, November 15, 2013, for shareholders of record as of Friday, November 8, 2013.

From September 1, 2013 to November 13, 2013, an additional 43,000 shares were issued as a result of options exercised.

**EMPLOYMENT AGREEMENT**

This Employment Agreement (the "Agreement") is made as of this 22nd day of August, 2013, by and between Simulations Plus, Inc., a California corporation (the "Company") and Walter S. Woltoz, an individual (the "Employee") with reference to the following facts:

- A. The Company desires to secure the services of the Employee as President and Chief Executive Officer.
- B. The Employee agrees to perform such services for the Company under the terms and conditions set forth in this Agreement.

In consideration of the mutual promises, covenants and conditions set forth herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is hereby agreed by and between the Company and the Employee as follows:

1. Representations and Warranties.

The Company represents and warrants that it is empowered under its Articles of Incorporation and Bylaws to enter into this Agreement. The Employee represents and warrants that he is under no employment contract, bond, confidentiality agreement, or any other obligation that would violate or be in conflict with the terms and conditions of this Agreement or encumber his performance of duties assigned to him by the Company. The Employee further represents and warrants that he has not signed or committed to any employment or consultant duties or other obligations that would divert his full attention from the duties assigned to him by the Company by this Agreement.

2. Employment and Duties.

The Company employs the Employee as President and Chief Executive Officer and the Employee hereby accepts such employment (the "Employment").

3. Term.

Subject to the provisions of Section 5, the term of this Agreement shall extend until August 31, 2014, commencing on September 1, 2013.

4. Compensation.

In full and complete consideration for the Employment, each and all of the services to be rendered to the Company by the Employee, and each and all of the representations, warranties, covenants, agreements and promises undertaken by the Employee pursuant to this Agreement, the Employee shall be entitled to receive compensation as follows:

4.1. Base Salary. The Employee shall receive from the Company a base salary of three hundred thousand dollars (\$300,000.00) per year, payable in equal, monthly installments. From each said salary payment the Company will withhold and pay to the proper governmental authorities any and all amounts required by law to be withheld for federal income tax, state income tax, federal Social Security tax, state disability insurance premiums, and any and all other amounts required by law to be withheld from the Employee's salary.

4.2. Grant of Option. The Employee shall be granted an option under the 2007 Stock Option Plan, exercisable for five (5) years, to purchase ten (10) shares of Common Stock for each one thousand dollars (\$1,000) of net income before taxes that the Company earns at the end of each fiscal year (up to a maximum of twenty thousand [20,000] options over the term of this Agreement) at an exercise price 10% over the market value per share as of the date of grant. The maximum number of options under this grant shall be adjusted accordingly for any stock split or reverse split after the date of this agreement. Option grants under this agreement shall be issued within ten days after the filing of the annual report (10-K) for the fiscal year for which the option is granted.

4.3 Performance Bonus. The Employee shall be paid a Performance Bonus in an amount equal to five percent (5%) of the Company's net income before taxes of the previous fiscal year, not to exceed \$60,000.

4.4. Benefits. Employer shall provide to Employee at the sole cost to Employer, and Employee shall be entitled to receive from Employer, such health insurance and other benefits which are appropriate to the office and position of Employee, adequate to the performance of his duties and not inconsistent with that which Employer customarily provides at the time to its other management employees. Employee's right to vacation and sick leave shall be determined in accordance with the policies of the Company as may be in effect from time to time and as are approved by the Company's Board of Directors. Employee shall have the right to reimbursement of customary, ordinary and necessary business expenses incurred in connection with the rendering of services and performance of the functions required hereunder in accordance with the policies of the Company as may be in effect from time to time and as are approved by the Company's Board of Directors. Such expenses are reimbursable only upon presentation by Employee of appropriate documentation pursuant to the policies adopted by the Company's Board of Directors.

## 5. Termination of Employment.

5.1. Expiration of the Term of Agreement. This Agreement shall be automatically terminated upon the expiration of the term of the agreement as described in paragraph 3 of this Agreement, or as sooner agreed by both Employee and Company in the event this Agreement is superseded by a new agreement. Upon such termination, the Company shall have no further liability to the Employee for any payment, compensation or benefit whatsoever under this Agreement.

5.2. By Death. This Agreement shall be terminated upon the death of the Employee. The Company's total liability in such event shall be limited to payment of the Employee's salary and benefits through the date of the Employee's death.



5.3. By Disability. If, in the sole opinion of the Company's Board of Directors, the Employee shall be prevented from properly performing his or her duties hereunder by reason of any physical or mental incapacity for a period of more than 90 days in the aggregate in any twelve month period, then, to the extent permitted by law, his or her employment with the Company shall terminate. The Company's total liability in such event shall be limited to payment of the Employee's salary and benefits through the effective date of termination upon disability.

5.4. For Cause. The Company reserves the right to terminate this Agreement immediately, at any time, if, in the reasonable opinion of the Company's Board of Directors: the Employee breaches or neglects the duties which he or she is required to perform under the terms of this Agreement; commits any material act of dishonesty, fraud, misrepresentation, or other act of moral turpitude; is guilty of gross carelessness or misconduct; fails to obey the lawful direction of the Company's Board of Directors; or acts in any way that has a direct, substantial and adverse effect on the Company's reputation. The Company's total liability to the Employee in the event of termination of the Employee's employment under this paragraph shall be limited to the payment of the Employee's salary and benefits through the effective date of termination.

5.5. Without Cause. The Company reserves the right to terminate this Agreement without cause for any reason whatsoever upon thirty (30) days' written notice to the Employee. Upon termination under this subsection, the Employee shall receive payment of an amount equal to twelve (12) months of the Employee's base salary or the Employee's base salary for the remaining term of this Agreement, whichever is greater. Other than payment of the amount as described in this paragraph, the Company shall have no further obligation to pay the Employee any other compensation or benefits whatsoever. The Employee hereby agrees that the Company may dismiss him or her under this paragraph 5.5 without regard (i) to any general or specific policies (whether written or oral) of the Company relating to the employment or termination of its employees, or (ii) to any statements made to the Employee, whether made orally or contained in any document, pertaining to the Employee's relationship with the Company.

5.6. Mutual Consent. This Agreement shall be terminated upon mutual written consent of the Company and the Employee. The Company's total liability to the Employee in the event of termination of the Employee's employment under this paragraph shall be limited to the payment of the Employee's compensation through the effective date of termination.

5.7. Termination of Obligations. Upon termination of employment for any reason whatsoever, the Employee shall be deemed to have resigned from all offices and directorships then held with the Company. Termination of employment shall have no effect on the Employee's position(s) on the Company's board of directors. The board of directors and shareholders will determine the Employee's eligibility to continue to serve as a member of the board.

6. Restrictions on Use or Disclosure of Confidential Matters, Proprietary Information and Trade Secrets.

6.1. During the term of this Agreement, the Employee may be dealing with trade secrets of the Company, including without limitation, customer lists, client contacts, financial information, inventions and processes, all of a confidential nature that are the Company's property and are used in the course of the Company's business. The Employee will not disclose to anyone, directly or indirectly, any of such trade secrets or use them other than as necessary in the course of his duties with the Company. All documents that the Employee prepares, or confidential information that might be given to him or that Employee himself might create in the course of his consultation with the Company, are the exclusive property of the Company. During the term of this Agreement and at any time thereafter, the Employee shall not publish, communicate, divulge, disclose or use any of such information which has been reasonably designated by the Company as proprietary or confidential or which from the surrounding circumstances the Employee knows, or has good reason to know, or should reasonably know, ought to be treated by the Employee as proprietary or confidential without the prior written consent of the Company, which consent may not be unreasonably withheld by the Company.

6.2. In the course of his employment for the Company, Employee will develop a personal relationship with the Company's customers and knowledge of those customer's affairs and requirements which may constitute the Company's only contact with such customers. Employee consequently agrees that it is reasonable and necessary for the protection of the goodwill and business of the Company that Employee make the covenants contained herein. Accordingly, Employee agrees that while he is in the Company's employ and for a one (1) year period after the termination of such employment for any reason whatsoever, he will not directly or indirectly:

(a) attempt in any manner to solicit from any customer (except on behalf of the Company) business of the type performed by the Company or to persuade any customer of the Company to cease to do business or reduce the amount of business which any such customer has customarily done or contemplates doing with the Company, whether or not the relationship with the Company and such customer was originally established in whole or in part through Employee's efforts; or

(b) engage in any business as, or own an interest in, directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or any other form of business entity if such business form or entity is engaged in the business in which the Company is engaged;

(c) render any services of the type rendered by the Company to or for any customer of the Company;

(d) employ or attempt to employ or assist anyone else to employ any person who is then or at any time during the preceding year in the Company's employ.

This entire Section 6 shall survive termination of this Agreement.

## 7. Company Property.

7.1. Any patents, inventions, discoveries, applications or processes, software and computer programs devised, planned, applied, created, discovered or invented by the Employee in the course of the engagement under this Agreement and which pertain to any aspect of the business of the Company, or its subsidiaries, affiliates or customers, shall be the sole and exclusive property of the Company, and the Employee shall make prompt report thereof to the Company and promptly execute any and all documents reasonably requested to assure the Company the full and complete ownership thereof.

7.2. All records, files, lists, drawings, documents, equipment and similar items relating to the Company's business which the Employee shall prepare or receive from the Company shall remain the Company's sole and exclusive property. Upon termination of this Agreement the Employee shall return promptly to the Company all property of the Company in his possession and the Employee represents and warrants that he will not copy, or cause to be copied, printed, summarized or compiled, any software, documents or other materials originating with and/or belonging to the Company, including, without limitation, documents or other materials created by the Employee for, or on behalf of, the Company. The Employee further represents and warrants that he will not retain in his possession any such software, documents or other materials in machine or human readable form.

7.3. This Section 7 shall survive termination of this Agreement.

8. Outside Activities. During the term of this Agreement, the Employee shall not, directly or indirectly, either as an officer, director, employee, representative, principal, partner, shareholder, employee, agent or in any other capacity, engage or assist any third party in engaging in any business competitive with the business of the Company, without the prior written consent of the Company, which consent may be withheld by the Company in its sole and absolute discretion. Following his employment with the Company, the Employee shall not engage in unfair competition with the Company, aid others in any unfair competition with the Company, in any way breach the confidence that the Company has placed in the Employee or misappropriate any proprietary information of the Company.

9. Reports. The Employee, when directed, shall provide written reports to the Company with respect to the services provided hereunder.

10. Strict Loyalty. The Employee hereby covenants and agrees to avoid all circumstances and actions that reasonably would place the Employee in a position of divided loyalty with respect to his obligations under this Agreement.

11. Assignment. This Agreement may not be assigned to another party by the Employee without the prior written consent of the Company, which consent may be withheld by the Company, in its sole and absolute discretion.

12. Arbitration. Except as otherwise provided herein in Section 15.11, any controversy between the Company and Employee in connection with this Agreement, including, without limitation, any dispute or claim arising from the voluntary or involuntary termination hereof, shall be settled by final and binding arbitration in Los Angeles, in accordance with the Commercial Arbitration Rules of the American Arbitration Association. Judgment of such award may be entered in a court of competent jurisdiction. Employee and the Company shall each pay the fees of his or its own attorneys, the expenses of his or its witnesses and all other fees and expenses connected with presenting his or its case at arbitration. All other costs of the arbitration, including, without limitation, the costs of any record or transcript of the arbitration proceedings, administrative fees, the fee for the arbitrator and all other fees and costs shall be borne equally by the Company and Employee.

13. Company Bylaws, Directions, Policies, Practices, Rules, Regulations and Procedures Employee agrees to become and remain thoroughly familiar with each and all of the Company's bylaws, directions, policies, practices, rules, regulations and procedures that relate to the employment and/or to any of Employee's duties and/or responsibilities as an employee of the Company and to abide fully and by each and all of such bylaws, directions, policies, practices, rules, regulations and procedures. During the term of employment, Employee shall be fully bound by and employed pursuant to each and all of the Company's bylaws, directions, policies, practices, rules, regulations and procedures as now in effect or as may be implemented, modified or otherwise put into effect by the Company during the term of employment, regardless of whether such bylaws, directions, policies, practices, rules, regulations and procedures are oral or are set forth in any manual, handbook or other document, and it is solely the responsibility of Employee to become and remain fully aware of and familiar with each and all such directions, policies, practices, rules, regulations and/or procedures. In the event of any conflict between any provision of this Agreement and any provision of the Company's directions, policies, practices, rules, regulations and/or procedures, the provisions of this Agreement govern for any and all purposes whatsoever.

14. Indemnification. The Company shall indemnify and hold Employee harmless from any and all claims, demands, judgments, liens, subrogation or costs incurred by Employee with respect to any shareholder derivative action or other claims or suits against the Company and/or its Board of Directors by individuals, firms or entities not a party to this Agreement to the maximum extent permitted under California law.

15. General.

15.1. Further Documents. Each party shall execute and deliver all further instruments, documents and papers, and shall perform any and all acts necessary reasonably requested by the other party, to give full force and effect to all of the terms and provisions of this Agreement.

15.2. Successors and Assigns. Except where expressly provided to the contrary, this Agreement, and all provisions hereof, shall inure to the benefit of and be binding upon the parties hereto, their successors in interest, assigns, administrators, executors, heirs and devisees.

15.3. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law. If any provision of this Agreement, as applied to any party or to any circumstance, shall be found by a court or arbitrator to be invalid or unenforceable under applicable law, such provision will be ineffective only to the extent of such invalidity or unenforceability, without invalidating or rendering unenforceable the remainder Of such provision and any such invalidity or unenforceability shall in no way affect any other provision of this Agreement, the application of any provision in any other circumstance or the validity or enforceability of this Agreement.

15.4. Notices. All notices or demands shall be in writing and shall be served personally, telegraphically or by express or certified mail. Service shall be deemed conclusively made at the time of service if personally served, at the time that the telegraphic agency confirms to the sender deliver thereof to the addressee if served telegraphically, 24 hours after deposit thereof in the United States mail properly addressed and postage prepaid, return receipt requested, if served by express Mail, and five days after deposit thereof in the United States mail, properly addressed and postage prepaid, return receipt requested, if served by certified mail. Any notice or demand to the Company shall be given to:

Simulations Plus, Inc.  
42505 10th Street West  
Lancaster, CA 93534-7059  
(661) 723-7723 Telephone  
(661) 723-5524 Facsimile  
Attention: Compensation Committee

and any notice or demand to the Employee shall be given to:

Mr. Walter S. Woltosz  
42505 10th Street West  
Lancaster, CA 93534-7059  
(661) 723-7723 Telephone  
(661) 723-5524 Facsimile

Any party may, by virtue of a written notice in compliance with this paragraph, alter or change the address or the identity of the person to whom any notice, or copy thereof, is to be sent.

15.5. Waiver. A waiver by any party of any of the terms and conditions of this Agreement in any one instance shall not be deemed or construed to be a waiver of the term or condition for the future, or of any subsequent breach thereof or of any other term or condition thereof. Any party may waive any term, provision or condition included for the benefit of that party. Any and all waivers shall be in writing.

15.6. Construction. This Agreement shall be governed by and construed in accordance with the laws of the State of California applicable to contracts entered into and fully to be performed therein without regard to its principles of choice of law or conflicts of law. In all matters of interpretation, whenever necessary to give effect to any provision of this Agreement, each gender shall include the others, the singular shall include the plural, the plural shall include the singular and the terms "and" and "or" may be used interchangeably as the context so requires or implies. The title of the sections of this Agreement are for convenience only and shall not in any way affect the interpretation of any provision or condition of this Agreement. All remedies, rights, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of any party.

15.7. Entire Understanding. This Agreement contains the entire understanding of the parties hereto relating to the subject matter contained herein and supersedes all prior and collateral agreements, understandings, statements and negotiation of the parties. Each party acknowledges that no representations, inducements or promises, oral or written, with reference to the subject matter hereof have been made other than as expressly set forth herein. This Agreement cannot be changed, rescinded or terminated orally.

15.8. Third Party Rights. The parties hereto do not intend to confer any rights or remedies upon any person other than the parties hereto and those referred to in Section 15.2 hereof so long as any such assignment by Employee was approved by the Company as provided in Section 11 hereof.

15.9. Attorneys' Fees. In the event of any litigation between the parties respecting or arising out of this Agreement, the prevailing party shall be entitled to recover reasonable legal fees and costs, whether or not the litigation proceeds to final judgment or determination.

15.10. Place of Litigation. Any litigation between the parties shall occur in the County of Los Angeles, California.

15.11. Injunctive Relief. Since a breach of the provisions of Sections 6, 7, 8 and 10 of this Agreement cannot adequately be compensated by monetary damages, the Company shall be entitled, in addition to any other right and remedy set forth in this Agreement or available to it at law, in equity or otherwise, to seek and obtain from any court of competent jurisdiction immediate temporary, preliminary and permanent injunctive relief restraining such breach or threatened breach, without the posting of any bond or other security therefor, against the Employee and against each and every other person, firm company, joint venture, and/or other entity concerned with and/or acting in concert with the Employee. Any such requirement of bond or other security is hereby expressly waived by the Employee, and the Employee expressly acknowledges that in the absence of such waiver, a bond or other security may be required by the court. The Employee hereby consents to the issuance of such injunction and expressly and knowingly waives any claim or defense that any adequate remedy at law might exist for any such breach or threatened breach. The Employee agrees that the provisions of Sections 6, 7, 8 and 10 of this Agreement are necessary and reasonable to protect the Company in the conduct of the business of the Company.

15.12. Counterparts. This Agreement may be executed in counterparts which, taken together, shall constitute the whole of the agreement between the parties.

IN WITNESS THEREOF, the parties have executed this Agreement as of the day and year first above written.

“Company” SIMULATIONS PLUS, INC.,  
a California corporation

By: /s/ Momoko Beran  
Title: Chief Financial Officer  
Date: 08/23/2013

“Employee” WALTER S. WOLTOSZ

By: /s/ Walter S. Woltosz  
Walter S. Woltosz  
Date: 08/22/2013

Compensation Committee:

By: /s/ David Z. D'Argenio  
Dr. David Z. D'Argenio  
Date: 08/22/2013

By: /s/ David L. Ralph  
Dr. David L. Ralph  
Date: 08/22/2013

By: /s/ Wayne H. Rosenberger  
Wayne H. Rosenberger  
Date: 08/22/2013

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-142882) and the incorporation by reference in the Form 10-K of our report dated November 15, 2013, with respect to the financial statements of Simulations Plus, Inc. as of and for the years ended August 31, 2013 and 2012, which report appears in the August 31, 2013 Annual Report on Form 10-K of Simulations Plus, Inc.

    /s/ Rose, Snyder & Jacobs    

Rose, Snyder & Jacobs LLP

Encino, California

November 15, 2013







**CERTIFICATIONS PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  
(18 U.S.C. SECTION 1350)**

In connection with the Annual Report of Simulations Plus, Inc., a California corporation (the "Company"), on Form 10-K for the year ended August 31, 2013, as filed with the Securities and Exchange Commission (the "Report"), Walter S. Woltosz, Chief Executive Officer of the Company, and Momoko A. Beran, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the report fairly presents, in all material respects, the financial condition and result of operations of the Company for the period covered by the Report.

/s/ Walter S. Woltosz

Walter S. Woltosz  
Chief Executive Officer  
November 15, 2013

/s/ Momoko A. Beran

Momoko A. Beran  
Chief Financial Officer  
November 15, 2013

(A signed original of this written statement required by Section 906 has been provided to Simulations Plus, Inc. and will be retained by Simulations Plus, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.)